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Abstract 
 
Clostridium difficile is regarded as the primary etiological agent of antibiotic-
associated diarrhoea, posing a significant challenge to healthcare facilities. The 
changing nature of C. difficile infection is causing an increase in associated 
disease occurrence outside of the healthcare setting and a gradual move away 
from the historical association with antimicrobial treatment. Adhesion of spores 
and vegetative cells to host gut epithelium is thought to be a key aspect of C. 
difficile virulence; disruption of this process may significantly reduce the impact 
of an infection and the likelihood of infection spread. Lipoproteins are involved 
in adhesion of C. difficile to host tissues and may have roles in other key 
aspects of virulence. Lipoproteins undergo a specific biosynthesis process 
within the bacterial cell involving addition of an acyl-glyceryl moiety by 
lipoprotein glyceryl transferase (Lgt) followed by signal peptide cleavage by 
lipoprotein signal peptidase (LspA); disruption of this process may cause 
attenuation of virulence and a reduction in adhesion to host tissue. C. difficile 
has been shown to encode two functional and homologous lipoprotein signal 
peptidases: LspA and LspA2. The novel antimicrobials globomycin and 
myxovirescin directly target lipoprotein signal peptidases and therefore may 
have potential for use in treatment of C. difficile infection. Evaluation of their 
efficacy against LspA and LspA2 can be determined by protection assays using 
Escherichia coli strains expressing LspA or LspA2 from C. difficile. 
In this study, both LspA and LspA2 from C. difficile are shown to contain the 
consensus sequences, domains and in silico predicted tertiary structure 
expected of lipoprotein signal peptidases. Characterisation of C. difficile strains 
with silencing mutations in either lspA or lspA2, in comparison to a wild type, 
reveals that the absence of either lipoprotein signal peptidase causes an 
increased survivability in hydrogen peroxide and may affect protein localisation 
within the bacterium. Finally, successful cloning of C. difficile lspA and lspA2 
and subsequent expression of LspA and LspA2 via auto-induction in E. coli is 
reported, paving the way for further investigation into the effect of globomycin or 
myxovirescin treatment. 
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Chapter 1. Introduction 
1.1. Clostridium difficile and lipoprotein biosynthesis 
Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacillus, 
considered to be the leading cause of antibiotic-associated diarrhoea (AAD). 
Pathogenic strains of C. difficile are recognised as major nosocomial pathogens 
(1) and increasingly, community-acquired pathogens (2). In recent years a 
decrease in incidence of Clostridium difficile infection (CDI) has been 
associated with an increase in infection control measures in hospitals (3, 4). 
Despite this, Clostridium difficile disease (CDD) is still a major factor in 
healthcare, with new strains exhibiting novel phenotypes constantly emerging, 
such as ribotype 332 which emerged in Scotland in May 2013 with a mortality 
rate of 75% (3/4) (5). 
While the usual clinical association with C. difficile is AAD, there is mounting 
evidence that CDD, or at least colonisation of the human gastrointestinal tract, 
can occur without pre-treatment with antibiotics (6), with as few as 36% of total 
CDI patients having been exposed to antibiotics in some studies (2, 7, 8). 
Initially, patients are taken off their existing courses of antimicrobials to examine 
potential for recovery and requirement for additional treatment (9, 10). There 
has been a shift towards automatic treatment with antimicrobials such as 
fidaxomicin and vancomycin because of the increased proportion of cases 
involving hypervirulent strains of C. difficile (10) such as the ribotype 027, 
toxinotype III, restriction endonuclease analysis BI and pulsed-field gel 
electrophoresis NAP1 strains (BI/NAP1/027).  
When a patient presents with CDD, symptoms can range from self-limiting 
diarrhoea (assumed to be AAD), through to pseudomembranous colitis which is 
fatal in up to 30% of cases (11). The clinical outcome is generally worsened by 
pre-existing conditions such as inflammatory bowel disease (IBD) or renal 
failure or administration of anti-peristaltic and immunosuppressant medications 
(12). These factors, combined with an ageing-related increased incidence (13) 
results in a much higher mortality rate among those aged over 60 years . 
Conversely, there is little evidence or theory to explain the increased isolation of 
C. difficile in infants where there is no evidence of  disease, with debate 
covering type of feed (14) and a simple lack of colonisation resistance (15). 
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Recently, attempts have been made to reduce the impact of severe cases of 
CDI. A valuable tool for reducing infection impact is predicting the severity and 
mortality of disease (16). Further, improving knowledge of the epidemiology and 
pathogenesis of C. difficile strains generally (17) and specifically contributes 
greatly towards understanding CDI, enabling better management of infection 
and disease. 
Lipoproteins are important virulence factors for bacteria (18, 19), and are 
involved in secretion, the spore cycle, antibiotic resistance (20) and adhesion 
(21) and form component parts of cellular machinery such as ATP-binding 
cassette transporters (22-25). As a result, lipoproteins and their biosynthesis 
are putative targets for antimicrobial therapy. Lipoprotein biosynthesis is a 
process common to all bacteria and involves a processing cascade of two 
enzymes in Gram-positive bacteria and three enzymes in Gram-negative 
bacteria. Inactivation of the enzymes involved has been shown to attenuate 
virulence in Gram-positive pathogens (26-28). One of the proteins involved in 
lipoprotein biosynthesis is lipoprotein signal peptidase (Lsp), a type II signal 
peptidase (SPaseII) (29). Lsp has been shown to contain five conserved amino 
acid sequence domains (30) which are in conserved locations within the tertiary 
structure which includes four transmembrane domains. It is thought that Lsp is a 
valid target for novel antimicrobials; the compound globomycin (31) and its 
derivatives (32) have been shown to target Lsp. Additionally, myxovirescin (33) 
also targets Lsp and is potentially better suited for use. C. difficile possesses 
two functional lipoprotein signal peptidases, LspA and LspA2, encoded by 
CD2597 (lspA) and CD1903 (lspA2) respectively (34-36). It is thought that 
targeting of one or both of these proteins with antimicrobials would significantly 
reduce the virulence of C. difficile, providing a novel route for treatment of 
infection and control of diseases caused by this pathogen. 
1.2. Pathogenicity of C. difficile 
1.2.1. Prevalence of infection 
Infection with C. difficile has frequently been described as epidemic due to the 
sudden increase in infection rate observed through the last decade. Much of 
this increase is attributed to the emergence of BI/NAP1/027 strains (37-40) 
which reportedly cause the most severe form of CDD and are thought to be the 
most infectious, with strains belonging to other ribotypes, including 078, also 
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showing prevalence among identified cases (17). It must be noted that ribotype 
027 is not the sole cause of severe and widespread cases of CDI. For example, 
in south east Scotland, ribotype 027 does not seem to be present, with ribotype 
001 the most prevalent (41) and in Spain ribotypes 014/020, 001 and 126/078 
are the most frequently reported (42). The total number of CDI cases globally 
has fallen in recent years, in particular in the United Kingdom, where cases 
have fallen steadily from 55,498 April 2007 to March 2008, to 14,687 April 2012 
to March 2013 (43). This fall is attributable to the implementation of mandatory 
reporting of cases with the initial aim to reduce national cases in the UK by 30% 
by 2011. In addition, the introduction of significant infection control measures 
have greatly reduced the likelihood of infection spread at least in the healthcare 
setting (3, 4).  
The community setting, outside of the healthcare environment, has an important 
role to play in the future of C. difficile infection, with indications that CDI in the 
community is more infectious but causes less serious symptoms. Surprisingly 
large numbers of cases of CDI are reported as community acquired (42, 44) 
and it has been suggested that many more go unreported with evidence that 
CDI is increasing in frequency (7, 45). Intriguingly, the common association of 
CDI with antibiotic treatment falls away when community acquired disease is 
examined, with reports of 49% having had no exposure to antibiotics in the 
previous 3 months (2, 6-8, 46). Also of note, due to implications for healthcare 
infection control. is an emerging relationship between community-acquired CDI 
and outpatient care (2, 45, 47), though most patients encounter only low-level 
outpatient care and are exposed to other potential sources of infection (46). 
C. difficile infection is not limited to humans; ribotype 078 commonly affects 
calves and pigs (48), and horses (49). This, coupled with the frequent isolation 
of C. difficile spores in foods (7, 50, 51), is causing some concern that some 
incidences of CDI may be acquired from food (52). There is also evidence that 
infective C. difficile can be waterborne (53) through environmental 
contamination with sewage effluent. 
1.2.2. Symptoms of infection 
Antibiotic-associated diarrhoea resulting from CDI is described as ranging from 
brief episodes of loose stools to diarrhoea similar to that caused by cholera, 
often with over 20 watery stools per day (54). The presence of colitis is 
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suggestive of the presence of C. difficile and can result in serious complications 
including toxic megacolon and leukocytosis which are parts of 
pseudomembranous colitis, which is fatal in up to 30% of cases (11). Other 
symptoms are outlined in the NHS Map of Medicine for Clostridium difficile (55) 
and include fever, bowel perforation and sepsis, with emphasis on the 
correlation of increasing white cell count with increasing severity, the 
emergence of a high temperature combined with evidence of severe colitis at 
the severe stage of disease and the emergence of hypotension, ileus and toxic 
megacolon at the life-threatening stage. 
1.2.3. Association with antibiotic treatment and other 
predispositions 
CDI is primarily associated with antibiotic use and other factors contribute as 
either predispositions or co-morbidities. The principal antibiotics that are thought 
to facilitate CDI are clindamycin, broad-spectrum cephalosporins, 
fluoroquinolones and β-lactams (8, 11, 56) though any antimicrobial has the 
potential to do so. The association between CDI and antibiotic use is that 
antimicrobials disrupt the normal gut flora of commensal bacteria (57), 
increasing the likelihood of infection by removing the inherent protective 
characteristics of the gut flora (58, 59). The actions of the commensals include 
providing a simple barrier to C. difficile vegetative cell adhesion to intestinal 
epithelia and remarkably complex signals to the host immune system (59). The 
nature of these signals may change during infection with C. difficile due to 
increased translocation of commensals through the epithelial barrier, increasing 
neutrophil recruitment (60). Thus a loss of commensals allows C. difficile 
adhesion to mucosa and epithelia and reduces the induction of an immune 
response. The association with antimicrobials runs deeper with some strains of 
the BI/NAP1/027 ribotype, where it has been demonstrated that low levels of 
ciprofloxacin, a fluoroquinolone, may induce higher levels  of toxin production by 
strains of this ribotype(61). Other medication-based associations include non-
steroidal anti-inflammatories (62) and gastric acid suppressors, in particular 
proton pump inhibitors (46, 62). 
There is a varied list of co-morbidities associated with CDI, including heart 
failure and gastroesophageal reflux disease (2), chronic kidney disease, chronic 
obstructive pulmonary disease and diabetes (63), immunosuppression, liver 
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failure and aspects of patient care such as the presence of a nasogastric tube 
(55). Many of these diseases are also strongly correlated with increasing patient 
age, indeed there is a high presence of culturable C. difficile in those aged over 
60 years (13). The effects of ageing, including decreased intestinal mobility and 
dietary changes combine with the increased rate of disease to elevate both the 
rate of development of CDI and the mortality rate Individuals may be colonised 
with C. difficile naturally and asymptomatically, infants in particular (13). The 
most serious pre-existing disease that acts both as a predisposing factor and 
co-morbidity is inflammatory bowel disease (IBD). Patients with IBD are more 
likely to contract CDI, resulting in a more severe course of disease (64, 65). 
Previous or concurrent gastrointestinal infections can also predispose a patient 
to CDI due to their disruptive effect upon the commensal gut flora, for example 
a fatal case that occurred after Salmonella serotype Saintpaul gastroenteritis 
(66). 
1.2.4. Pathogenesis pathway 
In general, C. difficile infections that lead to a manifesting disease follow a 
common pathogenesis pathway  (67), shown in Figure 1.1. Initially a set of 
factors, as discussed previously, are involved in disrupting the protective normal 
gut flora, allowing contaminating C. difficile to occupy the available niche and 
bind to enterocytes and the gut mucosa. The contaminating C. difficile could be 
exogenous spores, from the external environment, or endogenous, from an 
internal reservoir of infection, or self-contamination, including vegetative cells. 
Germination of spores follows contamination, a process that is not yet well 
understood, though bile slats appear to play a key role in stimulation (68, 69). 
Post-germination, colonisation factors such as surface layer proteins (70), 
lipoproteins (71) including the novel adhesin CD0873 (21) and other adhesins 
are expressed by the vegetative cell and promote adhesion followed by the 
establishment of a colony. Toxin production also begins, which causes a 
manifestation of symptoms. While some vegetative cells undergo normal 
cellular division, other cells produce spores which are then released to the 
surroundings to complete the cycle. The extent to which these steps are 
followed by a given strain varies greatly. Some strains are non-toxigenic and 
thus will not cause symptomatic disease, while others such as BI/NAP1/027 
strains overproduce toxins and thus cause a more severe disease. Other strains 
have a different response to germinants (72) and thus may cause a slower 
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onset of disease while others sporulate less readily, therefore a patient will 
release less spores into the environment (73). 
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Figure 1.1 Pathogenesis of C. difficile 
The pathway that C. difficile pathogenesis takes from initial predisposition to 
infection through to manifestation of symptoms and a potential for infection to 
other individuals is thought to be well conserved. Individuals usually become 
pre-disposed to infection by disruption of their normal intestinal microflora, 
allowing the development of a suitable niche for the germination of C. difficile 
spores and the attachment of vegetative cells via adhesins. This leads to an 
initial colonisation phase, immediately followed by production of toxins TcdA, 
TcdB and in some strains CDT. These toxins severely damage the gut wall, 
leading to manifestation of symptoms from a high volume of diarrhoea to 
pseudomembranous colitis. The infecting C. difficile population will start to form 
spores which will be released to the environment with the potential to infect 
other individuals or to re-infect the same individual.  
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1.3. Treatment of C. difficile Infection 
1.3.1. Current treatments 
Currently, there is a typical and standard approach to the treatment of CDI, C. 
difficile-associated diarrhoea (CDAD) and CDD. Initially, any existing treatment 
with antibiotics is halted allowing for recovery of the normal gut flora (55, 74). 
This has proven effective for C. difficile strains of lower virulence but severe 
cases require a more significant intervention. As such, therapy has been 
recommended in all cases, especially due to the increased prevalence of 
unknown or so called hypervirulent strains (9, 10). Initial therapy involves 
treatment with metronidazole for moderate cases, vancomycin for severe cases 
(55, 74) and also fidaxomicin where there is a high risk of recurrence (75); some 
of the few antibiotics that C. difficile does not show resistance to (9, 76). 
Likelihood of infection recurrence increases with each episode of disease; 
treatment strategies remain the same however fidaxomicin is the antimicrobial 
of choice (75, 77). In very severe cases where the patient is presenting with 
megacolon, perforation or septic shock, it can be necessary to perform a 
colectomy (75, 78) or other surgical procedures. In addition, the diarrhoeal 
element of the disease requires management by keeping the patient hydrated 
and administering electrolytes. 
1.3.2. Emerging treatments 
Alongside the standard methods described above, new methods for the 
treatment of disease caused by C. difficile are steadily being approved and 
adopted into the guidelines. Many of these methods are complementary to the 
primary antimicrobial treatment including administration of probiotics (79), 
biotherapy with yeasts such as Saccharomyces boulardii (75) and 
administration of other antimicrobial compounds such as teicoplanin, fusidic 
acid (76) and tirapazamine (80, 81). One method which is gaining considerable 
recognition is the use of donor stool in faecal transplant (82-85), a method 
which has been shown to cause rapid restoration of the patient’s microbiota in 
striking similarity to that of the donor, restoring both homeostatic and protective 
function (86). Similarly, there is evidence to suggest that deliberate patient 
colonisation with non-toxigenic strains of C. difficile can offer protection against 
challenge with toxigenic strains (87-89). Many of these methods, in particular 
those involving the administration of antimicrobial compounds, require 
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significant further testing before they will be recommended for use in the clinical 
setting (75). 
1.3.3. Future treatments 
Many more putative treatments being are yet to enter the clinical trial stage. 
There is a set of experimental antimicrobial compounds that have potential to 
be applied to C. difficile, including NVB302, a novel type B lantibiotic that 
inhibits cell wall biosynthesis (90), SMT19969, a novel, narrow-spectrum 
antibiotic being developed specifically for CDI (91) and globomycin (92). 
Approaches such as treatment with globomycin or its derivatives (32, 93) or the 
similar myxovirescin (33) aim to inhibit key aspects of virulence, preventing 
functions such as adhesion by lipoproteins (21, 31, 94) and are discussed in 
more detail in Section 1.7.3. Other future methods include targeting the primary 
toxins with antibodies (95), using equine serum, particularly in horses (96), and 
investigating the protective effects of the food glycome (97, 98). 
1.3.4. Prevention of infection and infection control measures 
The most significant impact on the number of reported cases of C. difficile 
infection is arguably the implementation of new, stricter regimes for the 
prevention and control of infection in the healthcare setting. There is evidence 
to suggest a great potential for infection of otherwise uncolonised patients with 
C. difficile spores from other patients (99), thus hand washing regimes for 
patients, visitors and staff have helped to reduce spread of disease. In addition, 
much research has been undertaken to evaluate methods for disinfecting wards 
or rooms (100-103), including the use of helium (104) and, in particular, 
hydrogen peroxide (105-107). Antimicrobials such as vancomycin and 
fidaxomicin have been shown to inhibit outgrowth of spores (77) and efforts to 
isolate patients immediately on suspicion of infectious diarrhoea (75) combine 
to reduce environmental contamination with spores.  
C. difficile is not restricted to the healthcare setting; the community acquired 
aspect of the disease cannot be ignored. This is a difficult aspect of the disease 
to investigate with many cases passing unreported (2). Work in this area is not 
limited to humans; with significant issues with CDI in horses (17, 49) and the 
bacterium has been isolated in meat products (50, 51). The reduction in disease 
incidence by redefining and maintaining standards in the healthcare setting has 
had a great impact on the disease however, more work is required to reduce 
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incidence in the community and to protect against the constantly changing 
nature of the infection. 
1.4. C. difficile toxins 
Typically, pathogenic C. difficile strains produce two toxins; TcdA and TcdB, 
and are thus termed toxigenic strains. TcdA and TcdB are encoded on the 
pathogenicity locus (PaLoc), formerly the toxigenicity locus (108), in conjunction 
with a set of genes thought to have toxin-related regulatory or secretory 
functions (109). The PaLoc is highly stable and conserved in toxigenic strains 
with non-toxigenic strains lacking the locus and strains with a defective PaLoc 
still able to cause disease (109). Some strains, notably BI/NAP1/027, also 
produce a binary toxin, CDT, encoded elsewhere in the genome, which 
functions similarly to the two primary toxins and may also contribute to virulence 
(110, 111). The effect and requirement of both primary toxins are unclear; 
evidence suggests that they act synergistically (112) with TcdB acting 
secondarily to TcdA but exploiting TcdA-induced tissue damage. Despite this, 
there is conflicting evidence that suggests that symptoms of C. difficile infection 
can be produced with TcdB alone (113-115) while strains producing TcdA alone 
have been shown to be avirulent (113). It has since been shown that mutant 
strains producing only one of the pair can cause disease and that a double 
mutant exhibits completely attenuated virulence (110, 116). In any case, it is 
accepted that the primary toxins, TcdA and TcdB, are responsible for causing 
the damage to the gut epithelium associated with CDD. 
1.4.1. Mechanism of action 
TcdA and TcdB display significant homology and could result from a gene 
duplication event. They are modular in structure (117) with three key domains: 
enzymatic, translocation and receptor binding (118); a structure which enables 
the toxins to function as Rho-glucosyltransferases (119), targeting the actin 
cytoskeleton of the host cell. After secretion from C. difficile, the toxins are 
internalised into the host cell via receptor-mediated endocytosis. The low pH 
environment within endosomes enables a conformational change within the 
toxin, leading to insertion into the endosomal membrane and thus translocation 
of the N-terminal enzymatic domain into the host cell cytosol (118). This domain 
then targets the small GTPase Rho as well as Rac and Cdc42 which are 
involved in regulation of the cell cycle, catalysing irreversible glucosylation and 
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inactivation. This halts the host cell’s ability to regulate its actin cytoskeleton, 
causing actin depolymerisation, loss of cell integrity and cell death. CDT has a 
similar end result; it is also translocated into the host cell where it acts as an 
actin-specific ADP-ribosyltransferase, again disrupting the cytoskeleton (111). 
CDT enters the host cell via receptor-mediated endocytosis after binding the 
lipolysis-stimulated lipoprotein receptor (LSR) and may cause clustering of this 
receptor into rafts (120). 
1.4.2. Regulation of expression and activity 
The primary toxins TcdA and TcdB are both encoded on the PaLoc, alongside 
genes tcdC, tcdE and tcdR, thought to encode regulatory functions (121). The 
arrangement of these genes in the PaLoc is shown in Figure 1.2. 
TcdE is thought to encode a holin protein that is required for secretion of the 
primary toxins (122, 123) though this is debatable as toxins have been shown to 
be released from a tcdE inactivation mutant (124).  
TcdR is thought to act as an alternative sigma factor, potentially allowing 
differential expression of the PaLoc by binding to RNA polymerase, providing a 
putative regulation step. There is evidence to suggest that tcdR expression is 
activated by SigD, a flagellar alternative sigma factor, and thus expression of 
tcdA and tcdB is activated (125). 
TcdC is a putative inhibitory regulator of transcription, however there is 
confusion about its role in the control of TcdA and TcdB synthesis. It is 
considered to be an anti-sigma factor; mutation has been shown to play an 
important role in the differentiation of hypervirulent strains, possibly through a 
loss of negative regulation (126). Conversely, measuring the transcription levels 
of genes within the PaLoc and expression of TcdA and TcdB in a tcdC mutant 
of the 630Δerm strain of C. difficile revealed only minor differences when 
compared to the wild type (127). A similar result was achieved using the 
R20291 strain, from ribotype 027, which has both a frame shift mutation and a 
deletion within the tcdC gene; these mutations were restored using an allelic 
exchange system, demonstrating that tcdC genotype bears no association with 
toxin production (128). 
A wide variety of factors have been implicated in regulation of toxin expression, 
including flagellar components (129) and the AgrA transcriptional regulator 
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acting through c-di-GMP (125, 130). Recently a single toxin-antitoxin system, 
MazEF-cd, has been found in C. difficile and affects many parts of 
pathogenesis, possibly including toxin production (131). 
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Figure 1.2 The C. difficile 630 PaLoc 
The two primary toxins of C. difficile, TcdA and TcdB, are encoded together on 
a genomic region named the PaLoc. This region also encodes genes with the 
following putative regulatory functions: tcdE a secretion-related holin; tcdR an 
alternative sigma factor and tcdC an inhibitory regulator of transcription. 
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1.4.3. Toxin variation among strains 
There is variation in toxin expression between strains of C. difficile and as such 
a toxinotyping system has been devised which improves upon the previously 
established serotyping system (132, 133). There are currently 36 
distinguishable toxinotypes with designations from 0 through to XXXI (134). 
These toxinotypes are determined by the expression of TcdA, TcdB and CDT 
and also by the particular variant of each gene; there are natural variations in 
the PaLoc and CDT, resulting in differing profiles. Such variations can affect the 
production and properties of each toxin and arise from events such as 
insertions and deletions (133). For example, an epidemic isolate of 
BI/NAP1/027, isolated in Quebec, Canada, has been characterised as 
toxinotype III, with production of TcdA and TcdB 16 and 23 times higher than a 
toxinotype 0 reference (135). This suggests a relationship between toxinotype 
and disease severity however there is no direct correlation (136).  
1.5. Sporulation and germination in C. difficile 
Spores are the infectious agent of C. difficile and thus the key vehicle of 
pathogenesis for C. difficile. They are produced when vegetative cells enter a 
period of high stress, usually severe nutrient deficiency, and are a very resilient 
form of the organism which can withstand most cleaning and sterilisation efforts 
(17). Most understanding of sporulation and germination comes from studies of 
Bacillus subtilis however recent work has shown that there are considerable 
differences within the Firmicutes (137, 138), revealing the need for specific 
studies in C. difficile.  
1.5.1. Regulation of sporulation and germination 
Regulation of sporulation is a complex process that is becoming more 
understood. There are at least 225 genes in the sporulation pathway, possibly 
representing a simpler ancestral version of sporulation in Firmicutes (138). 
Expression of these genes is controlled by a set of alternative sigma factors:  σF, 
σE, σG and σK plus Spo0A, the master sporulation regulator (137), which is itself 
controlled by the transition phase sigma factor SigH (139). These sigma factors 
are activated in a cascade of conserved periods of activity that controls the 
progression of endospore formation (140). Following initiation of asymmetric 
division controlled by Spo0A, σF and σE control early stages and σG and σK 
control late stages in the mother cell and the forespore respectively. After spore 
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maturation the mother cell autolyses, releasing the spore. 
CDI cannot occur without germination and outgrowth of spores. Therefore there 
are a number of crucial processes that allow correct germination. At least 511 
genes are differentially regulated during germination with co-regulation of 
functional groups of proteins (141). Key processes include lysis of the spore 
cortex by SleC (142) in conjunction with the serine protease CspB (143). The 
spore coat and surface layer carries out other functions both during assembly 
and into infection with proteins identified as a superoxide dismutase, a 
manganese catalase and a bifunctional peroxiredoxin and chitinase (144, 145). 
After germination to vegetative growth, virulence factors such as adhesins (70, 
71) and toxins are produced.  
1.5.2. Response to bile salts 
While bacteria such as B. subtilis germinate in response to nutrient stimuli, C. 
difficile does not appear to possess versions of germinant receptors that are 
found in other bacteria (146). It has been shown that components of bile, 
particularly the cholate derivative taurocholate, with glycine as a cogerminant, 
can cause germination initiation both in vitro (68, 69) and in vivo (147). It has 
been proposed that these germinants are recognised by a specific protease: 
CspC, and that bile acid-mediated germination is important for disease in a 
hamster model of infection (148). The mechanism of taurocholate and glycine 
binding to a receptor is complex, especially with the addition of a putative 
germination inhibitor, chenodeoxycholate (149). Chenodeoxycholate is a 
cholate derivative metabolite produced by normal gut flora, proposed as a 
natural inhibitor of C. difficile germination (150), revealing a mechanism for 
preferred germination in antibiotic-treated individuals (149). 
The situation is complicated by substantial evidence that strains vary in their 
response to these three compounds (72). This diversity runs deeper than 
chemical responses; many strains display differing rates and extents of 
germination (73, 151). It was thought that such diversity explained the 
“hypervirulence” of certain strains, but there is more variation from strain to 
strain than type to type (152, 153).  
In the Bacillales, the signals from germinant receptors enter a transduction 
pathway that passes the signal to downstream effectors. The first key step in 
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this pathway is performed by the spore germination protein GerD (154, 155), 
which functions in both signal transduction and in clustering of germinant 
receptors into germinosomes (154). In Clostridiales, there is no obvious 
homolog of GerD however, the overall signal transduction process is the same 
indicating the presence of an alternative (155). GerD has been shown to 
localise to the inner membrane of Bacillus subtilis spores and analysis has 
shown it to be a lipoprotein (156). It may also localise to other parts of the spore 
however, because the protein appears to be shed during germination (156), 
where GerD is associated with the inner membrane it is most likely to be 
functional and this localisation is the most appropriate for any interaction with 
germination receptors and downstream effectors (157). This evidence suggests 
that the protein that the Clostridiales order uses to perform the function of GerD 
is a lipoprotein, localised to a similar part of the spore. 
1.6. Bacterial Adhesion 
The first step in CDI is thought to be adhesion of live cells to exposed colonic 
epithelia. This process is mediated by components of the bacterial surface layer 
called adhesins; in C. difficile these include the surface layer protein SlpA (158), 
members of the cell wall protein family (70), components of the flagella (159, 
160) and a lipoprotein called CD0873 (21).  
1.6.1. Surface layer proteins and adhesins 
The outermost layer of bacteria is a proteinacious network which has important 
roles in growth and survival (161) and is termed the surface or S- layer. The S-
layer has two primary constituents; the monomeric high- and low-molecular 
weight surface layer proteins (SLPs) which bind non-covalently together to form 
the H/L complex (162), a regularly spaced 2 dimensional array (161). These 
proteins follow dedicated pathways of secretion and anchoring to the bacterial 
cell wall; the majority of translocation of these and other proteins across the cell 
membrane is performed by the Sec secretion system, of which C. difficile has 
two (162). 
Once anchored to the cell wall SLPs play an important role in virulence of 
bacterial pathogens including C. difficile, specifically in adhesion to host tissues 
and interaction with the host immune system (161). For example, the human 
toll-like receptor 4 (TLR4) found on the surface of immature dendritic cells, has 
been shown to recognise C. difficile SLPs, causing the maturation of these 
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dendritic cells, generation of T-cell helper cells thus activating both innate and 
active immune systems (163). Of the two SLPs, the high-molecular weight 
protein has been shown to be the most involved in C. difficile binding to host 
cells via two major polypeptides and ligands in the extracellular matrix including 
collagen I, thrombospondin and vitronectin (70). Other proteins in the S-layer 
have been shown to be involved in adhesion to the host including CbpA which 
has high binding affinity to collagen I and collagen V (164) and members of the 
cell wall protein (CWP) family which has significant homology to the SLPs (70, 
161). CWP proteins have other roles besides host adhesion; for example CwpV 
has a conserved aggregation-promoting function by which it may assist in 
anchoring neighbouring cells (165). One major contribution to adherence of C. 
difficile to the host appears to come from SlpA (158) with variations in the 
encoding gene allowing identification of strains though this does not alter the 
adhesion properties of the particular strain (166). Another significant 
contribution comes from flagellar components, as specifically demonstrated in 
the 027/BI/NAP1 R20291 strain, in a study which also demonstrated inter-strain 
variation; the 630Δerm strain does not require flagellar components for 
colonisation (160). 
1.6.2. Lipoproteins 
Lipoproteins are a set of proteins grouped by their method of secretion and 
anchoring which perform many important functions in bacteria. These functions 
include roles in protein secretion, the spore cycle, sensory systems, antibiotic 
resistance and adhesion (20, 21), biogenesis of other systems (167) and 
protection from superoxide (168). Lipoproteins appear to be particularly involved 
in transport systems, ATP-binding cassette (ABC) transporters in particular (23-
25, 169), and are frequently shown to be required for virulence (18, 19, 24). In 
Gram-negative bacteria lipoprotein biosynthesis appears to be essential for 
viability while the process may be dispensable in Gram-positive bacteria (22). 
Of particular interest to this study is the potential for a role of lipoproteins in the 
adhesion of C. difficile spores and vegetative cells to host tissue with the 
lipoprotein CD0873 having been recently identified as a definitive adhesin, the 
first such identification in C. difficile (21).   
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1.7. Lipoprotein biosynthesis 
Lipoprotein biosynthesis in its simplest form is common to both Gram-positive 
(Figure 1.3) and Gram-negative bacteria. Initially, the translated pre-
prolipoprotein undergoes modification with a diacylglyceryl moiety by lipoprotein 
diacylglyceryl transferase (Lgt) at a conserved cysteine residue within the so 
called lipobox of the protein (22, 170). This prolipoprotein then undergoes signal 
peptide cleavage at the cysteine residue by lipoprotein signal peptidase (LspA), 
a type II signal peptidase, to form what constitutes a mature lipoprotein in 
Gram-positive bacteria. Gram-negative bacteria and some Gram-positive 
bacteria have a final step in which a third acyl moiety is added to the N-terminus 
of the cysteine by lipoprotein N-acyl transferase (Lnt). The two or three acyl 
moieties enable insertion of the lipoprotein into the cell membrane and it is 
suggested that the third moiety in Gram-negative bacteria could have a role in 
localisation. 
Inactivation of the enzymes involved in lipoprotein biosynthesis have been 
shown to attenuate virulence in Gram-positive pathogens such as 
Mycobacterium tuberculosis (26, 27) and Bacillus anthracis (28) however this 
does not seem to hold true for all, Streptococcus suis for example (171). Full 
virulence studies have not been conducted in other species where lipoprotein 
biosynthesis has been disrupted but these bacteria do display substantial 
differences in growth and other phenotypes (172-176).  
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Figure 1.3 Lipoprotein biosynthesis in Gram-positive bacteria 
All types of bacteria follow the same conserved mechanism for the biosynthesis 
of lipoproteins except that Gram-negative and mycobacteria perform additional 
steps in accordance with their additional protein- localisation requirements. 
Gram-positive bacteria preform the minima of steps: initially a freshly translated 
pre-prolipoprotein is modified with a diacyl-glyceryl moiety at a conserved 
cysteine residue within the lipobox region of the signal peptide by lipoprotein 
glyceryl transferase (Lgt). The resultant prolipoprotein is then modified via the 
cleavage of the signal peptide immediately upstream of the conserved cysteine 
residue by lipoprotein signal peptidase (Lsp), producing a mature lipoprotein.  
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1.7.1. Lipoprotein signal peptidase 
The structure of a protein is closely related to its function; primary structure 
places the required functional and structural amino acids in the desired order, 
secondary structure folds the protein into helices and sheets that allow the 
tertiary structure to fold the protein into a conformation that brings the amino 
acids for the active site into correct alignment and permits interaction by the 
protein with the cell. A lipoprotein signal peptidase (Lsp) or signal peptidase II 
(SPaseII) has a specific predicted structure, first reported in Tjalsma et al (30), 
based upon studies in B. subtilis. Tjalsma et al (30) also reports on analysis of 
the amino acid sequences of other bacteria and concludes that there are five 
conserved sequence domains between all proteins. This conclusion is 
supported by later work in Rahman et al (177) and Paetzel et al (29), in which 
the nomenclature of the domains were changed from I through V to A through 
E. The tertiary structure of lipoprotein signal peptidases, including the 
approximate expected locations for the five conserved amino acid sequence 
domains is shown in Figure 1.4, reproduced from Paetzel et al (29), and has 
been predicted by various membrane topology predicting algorithms in that 
study, Tjalsma et al (30) and, more recently, in Dalbey et al (178). All agree that 
the protein should take on a four transmembrane domain structure which allows 
localisation of the conserved domains to important positions. Specifically 
domains C and D, which contain the two aspartic acid residues thought to form 
the active site. A model mechanism for the proteolytic cleavage of signal 
peptides is also displayed in Figure 1.4. While the five conserved amino acid 
domains are thought to contain conserved sequences, the exact sequence 
location of each domain within each protein is subject to variation. They do not 
occur at a given amino acid number though they do always occur in order. The 
predicted amino acid sequence of each domain has changed between studies 
while the positioning and general composition of the domains has remained the 
same. The sequences of each domain given in each study are shown in Table 
1. 
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Table 1 Lipoprotein signal peptidase or Signal peptidase II conserved 
domain expected sequences 
The amino acid sequences of the five conserved domains predicted across 
lipoprotein signal peptidases are given according to the study that reported 
them. The relative frequency of each amino acid in consensus sequences is 
denoted by the type of lettering: uppercase indicates a very high frequency; 
lowercase indicates a low frequency and ‘x’ indicates no evidence of 
conservation at that residue. Amino acid frequency or level of conservation was 
not analysed by Rahman et al (177). 
Domain 
Tjalsma et al 
(30) 
Paetzel et al 
(29) 
Rahman et al 
(177) 
    
A dqxxk dxxtk DQLSK 
B NxGaaf NxGaaf NYGISF 
C ixggalgNxxDr iiggaxIgNxxDr VIGGAVGNLIDR 
D VvD vvd VFD 
E FNxAD FNxAD FNLAD 
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Figure 1.4 Schematic of type II signal peptidase structure and proteolytic 
mechanism 
Figure reprinted from Paetzel M, Karla A, Strynadka NC, Dalbey RE. Signal 
peptidases. Chemical reviews. 2002 Dec;102(12):4549-80.(29). Copyright 2014 
American Chemical Society. Showing, A: the expected membrane topology of 
type II signal peptidases as first reported in Tjalsma et al (30), showing the 
approximate positions of active amino acids (Aspartic acid, Asp, D in white 
letters) and the conserved amino acid domains (A through E; labelling error 
carried over from the original) [green boxes]. B: the predicted proteolytic 
mechanism of signal peptide cleavage performed by this type of enzyme. 
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There is a number of reasons for the variation in reported sequences. The study 
by Rahman et al (177) focussed on proteins from bacteria closely related to 
Rickettsia typhi and only examined 10 genes. The original study, Tjalsma et al 
(30), used 19 genes, representing a retrospective improvement in terms of 
representation of the majority of bacteria. Paetzel et al (29) examined 54 genes, 
representing the best set of all studies. However, due to the small numbers of 
species sampled in each study. not one of these studies should be considered 
the superior source for the sequence of these domains. Despite the potential for 
variation in the absolute common sequence of each domain their general form 
remains the same, providing an indicator for the functionality of these proteins. 
As a result of the data presented in these studies, it is clear that a lipoprotein 
signal peptidase has a number of features; the presence of the five conserved 
domains approximately located to allow function by the tertiary structure which 
includes the four transmembrane domains. 
1.7.2. Targeting of the lipoprotein biosynthesis pathway 
Lipoprotein biosynthesis is clearly a potential target for the development of 
novel antimicrobials due to the importance of this process for Gram-negative 
viability and Gram-positive virulence. It is thought that, even if these 
antimicrobials were not completely bactericidal and instead decreased virulence 
and in particular prevented bacterial adhesion, they would be highly effective 
against CDI. One emerging antimicrobial that has specific action against LspA 
is globomycin. It was initially shown that globomycin treatment caused an 
increase in levels of prolipoprotein in Escherichia coli associated with an 
inhibition of growth and that lipoprotein-negative mutants were resistant to 
globomycin (179). Subsequently, it was shown that the action was specific to 
LspA, and that it was non-competitive and tighter than the binding of the 
prolipoprotein substrate (31). Globomycin may have additional actions on other 
aspects of the bacteria that cause lethality as it was shown to kill M. 
tuberculosis independently of LspA (180) however this does not detract from its 
potential for use as an antimicrobial. It has been shown that analogues of 
globomycin can, in fact, have more potent activity than globomycin itself (32) 
and that the variation in activity between analogues is structure-dependent 
(181). Experiments to evaluate the antimicrobial activity of globomycin against 
C. difficile would shed valuable light on its suitability for targeting lipoprotein 
signal peptidases in this organism. Protection assays with E. coli expressing C. 
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difficile LspA or LspA2 such as those performed by Rahman et al (177) and 
Khandavilli et al (24) would provide evidence that these enzymes are targets of 
globomycin in C. difficile and that other factors are not involved.  
1.7.3. Globomycin alternatives 
Until recently, there has been a very low availability of globomycin, partly due to 
the challenges posed by synthesis. Alternatives exist that allow feasibility 
testing while other compounds such as the aforementioned analogues may 
prove to be better candidates. The common antimicrobial and spore stain 
malachite green that has been used to treat infections in fish and humans prior 
to emerging evidence on its toxic properties has been shown to interfere with 
the growth of bacteria such as M. tuberculosis (182). The antimicrobial activity 
of malachite green stems from its action as a respiratory enzyme poison (183). 
It was subsequently shown that lipoprotein biosynthesis is essential for the 
resistance of M. tuberculosis to malachite green via the generation of an lspA 
mutant strain (184). A strain mutant in the P27-P55 operon which encodes P55, 
an efflux pump, was shown to be hypersensitive to malachite green and also 
caused more rapid decolourisation of the compound (185). Decolourisation of 
malachite green is generally caused by reduction to leucomalachite green, a 
colourless and water-insoluble compound, thought to occur very slowly in the 
absence of air (183). Intestinal bacteria have been shown to perform this 
reduction (186),  typically using an enzyme called triphenylmethane reductase 
(Tmr) (187). The latter study also demonstrated that lipoproteins are involved in 
the effective sequestration of malachite green away from Tmr and it is thought 
that such sequestration could reduce the toxicity of malachite green to bacteria 
by sequestration away from respiratory enzymes. It is suggested that malachite 
green could be used to assay the requirement of lipoprotein biosynthesis in 
resistance of a bacterial species to this toxic stress and thus shed light on the 
likely outcome of the use of globomycin as an antimicrobial against that 
bacterium. 
As a potential alternative to rare globomycin, the Myxobacterium secondary 
metabolite myxovirescin, or TA had been shown to inhibit LspA (33, 188). This 
study also compared the effects of myxovirescin to those of globomycin and 
found that myxovirescin has a better whole-cell potency and thus may, in fact, 
be a better option for treatment of CDI and associated diseases than 
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globomycin. Myxococcus xanthus, the myxovirescin producer strain, has four 
different lipoprotein signal peptidases which have recently been shown to have 
potential roles in protection against myxovirescin (33, 188), indicating that the 
previously mentioned protection assays could be used with this compound. 
Similar to globomycin, myxovirescin is difficult to obtain and purify (189-191) 
however the paper that initially identified myxovirescin as an inhibitor of LspA 
utilised a lawn of an M. xanthus strain that overproduces the compound; an 
approach that would be difficile to implement in C. difficile due to the need 
incubation under anaerobic conditions.  
1.8. Project Aim 
In previous work, it was shown that C. difficile encodes two potential lipoprotein 
signal peptidases, LspA and LspA2 (34-36). LspA2 was initially considered as a 
lipoprotein signal peptidase as the gene encoding this protein, CD1903, was 
potentially paralogous to lspA, CD2597, in C. difficile and orthologous to LspA-
encoding genes in other bacteria (Figure 1.5). LspA2 is a putative functional 
homolog of LspA and contains the key set of functional amino acids found in 
type II signal peptidases. Previous work used targeted insertional mutagenesis 
via the ClosTron system (192-194) to generate mutant strains in either lspA (C. 
difficile ECF1) or lspA2 (C. difficile ECF2) and demonstrated that both strains 
display increased sensitivity to malachite green (Figure 1.6) thus indicating their 
involvement in lipoprotein processing.  
Another method for characterising the functionality of LspA and LspA2 is a 
globomycin protection assay, as used in Rahman et al (177) and Khandavilli et 
al (24). This assay relies upon the expression of a non-native lipoprotein signal 
peptidase in E. coli to cause a decrease in globomycin susceptibility. To 
achieve this, C. difficile lspA and lspA2 would need to be separately cloned into 
an expression vector that would allow induction of expression of each protein 
once the vector was transformed into E. coli. The strains generated could then 
be subjected to globomycin treatment with and without induction of expression 
and the survival of each strain calculated. 
There are other aspects of lipoprotein biosynthesis in C. difficile and the effects 
of its disruption on bacterial phenotype that need to be investigated. There is 
evidence that disruption of certain lipoproteins causes increased susceptibility 
to oxidative stress (168) and that there is a link between susceptibility to 
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oxidative stress and adhesion (195). Knowledge of the effect of these mutations 
on the sensitivity of C. difficile to other existing antimicrobials may also shed 
light on the best course of action to pursue with regards to the development of a 
novel antimicrobial that exploits lipoprotein biosynthesis.  
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Figure 1.5 Alignment of the amino acid sequences of C. difficile LspA and 
a functional homolog LspA2 to homologs in E. coli and S. pneumoniae, 
demonstrating the presence of conserved regions 
An alignment of the amino acid sequences of the C. difficile proteins encoded 
by genes CD25870 (LspA) and CD19030 (LspA2) to orthologous proteins in 
Escherichia coli and Streptococcus pneumoniae, as shown in Farries, 2012 
(34). There are clear conserved residues across all 4 proteins indicating a 
potential for a common function, suggesting that LspA2 may be a paralog of 
LspA. 
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Figure 1.6 Sensitivity of lspA and lspA2 mutants of C. difficile to malachite 
green 
C. difficile strains mutant in either lspA or lspA2 were grown alongside the C. 
difficile 630Δerm wild type strain in the presence of malachite green, an 
antimicrobial. Colony forming units (CFU) of each were enumerated and plotted 
graphically, indicating that both mutant strains are more susceptible than the 
wild type and that the lspA2 mutant strain is the more susceptible of the two. 
Statistics displayed:  * indicates a P-value ≤ 0.05, ** indicates a P-value ≤ 0.01. 
Statistical P-values were calculated in Microsoft Excel using a Bonferroni 
correction comparing mutant strains to the wild type after a two-tailed ANOVA 
performed by the Data Analysis Toolpack. Figure adapted from Farries et al, 
2013 (36). 
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This study aims to further characterise the phenotypes of C. difficile strains 
ECF1 and ECF2 by analysis of growth characteristics and response to 
hydrogen peroxide. This study also aims to analyse the two C. difficile 
lipoprotein signal peptidases, LspA and LspA2, bioinformatically and by 
generating E. coli strains capable of expressing C. difficile 630 LspA or LspA2 
for use in globomycin protection assays.  
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Chapter 2. Materials and Methods 
2.1. Bacterial strains and growth conditions 
2.1.1. General bacterial growth conditions 
The strains used in this study are listed in Table 2. Liquid cultures of E. coli 
strains were grown in Luria Bertani (LB) broth [Miller] at 37°C with 200 rpm 
orbital shaking unless otherwise stated. Plate cultures of E. coli were grown on 
Luria Bertani broth [Miller], supplemented with No2 Bacteriological Agar [Fisher] 
at 37°C. Liquid cultures of C. difficile were grown in Brain Heart Infusion (BHI) 
Broth [Sigma, or Oxoid] at 37°C and 70% humidity in a Don Whitley DG 500 
Anaerobic Workstation supplied with BOC Anaerobic Mix gas (10% CO2, 10% 
H2, N2). Plate cultures of C. difficile were grown on BHI Agar [Oxoid] under the 
same conditions. Supplements and antibiotics appropriate to the strain or 
experiment being performed were added to the growth media where required.  
E. coli Rosetta2 (DE3) cultures were always grown in media supplemented with 
2% glucose to inhibit induction of protein expression unless desired and 
chloramphenicol at a concentration of 34 µg ml-1 to select for the pRARE2 
plasmid, with the addition of other antibiotics as required. Where used, other 
antibiotics were used at the following concentrations: 75 µg ml-1kanamycin; 5 µg 
ml-1erythromycin: 100 µg ml-1ampicillin. Agar plates used in transformations of 
pGEM-T Easy plasmids were also supplemented with 0.5 mM IPTG and 80 µg 
ml-1X-Gal. 
2.1.2. Chemically competent Escherichia coli 
Chemically competent cultures of E. coli strains DH5α, TOP10 and Rosetta 
2(DE3) were generated by growing cultures in 100 ml LB medium at 37°C and 
200 rpm shaking to an OD595 of 0.5 – 0.7. Culture was then incubated on ice for 
10 minutes followed by centrifugation at 4,000 x g and 4°C for 10 minutes. Cells 
were resuspended in 50 ml sterile, ice cold 0.1 M CaCl2 solution and incubated 
on ice for 30 minutes. Cells were centrifuged as before and resuspended in 600 
µl 0.1 M CaCl2 followed by the addition of 300 µl 50% glycerol, aliquoting 200 µl 
to 1.5 ml Eppendorf tubes and storage at -80°C or immediate use in 
transformation experiments. 
E. coli HB101 chemically competent cells were purchased from Promega, UK 
and used according to the manufacturer’s specifications.  
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Table 2 Bacterial strains used in this study 
Strain Relevant Genotype Description Source 
    
C. difficile 630 Δerm  
Laboratory strain, used 
as w ild type 
Hussain 
et al (196) 
C. difficile ECF1 ΔlspA (CD25970::ermB::321¦322) 
C. difficile 630Δerm lspA 
ClosTron mutant. ErmR 
Previous 
w ork (34) 
C. difficile ECF2 ΔlspA2 (CD19030::ermB::317¦318) 
C. difficile 630Δerm lspA2 
ClosTron mutant. ErmR 
Previous 
w ork (34) 
C. difficile 630Δerm 
Δlgt 
Δlgt::ermB 
C. difficile 630Δerm lgt 
ClosTron mutant. ErmR 
Gift from 
A. 
Kovacs-
Simon 
C. difficile KSA1 CD0873::ermB::317¦318  
C. difficile 630Δerm 
CD0873 ClosTron 
mutant. ErmR 
A. 
Kovacs-
Simon et 
al (21) 
E. coli DH5α  
High-eff iciency 
transformation strain 
Invitrogen 
E. coli TOP10  
High-eff iciency 
transformation strain 
Invitrogen 
E. coli Rosetta2(DE3) pRARE2 CamR 
Expression strain able to 
produce tRNAs for rare 
codons 
Novagen 
E. coli HB101  
High-eff iciency 
transformation strain 
Promega 
E. coli C43 (DE3) 
(BL21)  
 Expression strain, 
tolerant to toxic proteins 
(197) 
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2.2. Plasmids used and generated in this study 
The plasmids used in this study are listed in Table 3. The construction of 
plasmids produced by this study is explained in Section 2.10.2. 
Table 3 Plasmids used in this study 
Plasmid Characteristics Source 
   
pQE80 
Expression plasmid: AmpR CamR N-
terminal 6xHis 
Quiagen 
pBAT4 Expression plasmid: AmpR lacI T7lac 
Peränen et al 
(198) 
pET28a 
Expression plasmid: KanR lacI C-
terminal 6xHis 
Novagen 
pGEM-T Easy TA cloning vector, AmpR lacZ Promega 
pRL4A pQE80/(His-)CD1903 
R. Law rence, 
unpublished 
pRL6A pQE80/(His-)CD2597 
R. Law rence, 
unpublished 
pEF10 pBAT4/mCD2597-His This study 
pEF11 pBAT4/iCD2597-His This study 
pEF12 pBAT4/mCD1903-His This study 
pEF13 pBAT4/iCD1903-His This study 
pGEM-T 
Easy::CD2597pET 
Intermediate plasmid for pEF14 This study 
pGEM-T 
Easy::CD1903pET 
Intermediate plasmid for pEF15 This study 
pEF14 pET28a/CD2597(-His) This study 
pEF15 pET28a/CD1903(-His) This study 
pNIC-KSA1 pNIC28 carrying CD0873 
A. Kovacs-
Simon et al 
(21) 
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2.3. Oligonucleotide primers used in this study 
The oligonucleotide primers used for PCR in this study are shown in Table 4. 
Name Sequence Characteristics 
   
CD2597_pBAT4_F TCCATGGCTATGCTATATATATTAATAATA 
PCR for pEF10 insert with 
base insertion and Nco1 site 
CD2597_pBAT4_F2 CCCATGGCTTATATATTAATAATAATTCTA 
PCR for pEF11 insert with 
base deletion and Nco1 site 
CD2597_pBAT4_R 
CCCATGGTTAGTGGTGGTGGTGGTGGTG
CCTACTTTTACTTTCAAAAAAT 
PCR for pEF10 and pEF11 
with His tag and Nco1 site 
CD1903_pBAT4_F 
TCCATGGCTATGCAAGGAGGTGTTAATA
TC 
PCR for pEF12 with base 
insertion and Nco1 site 
CD1903_pBAT4_F2 
TCCATGGCTGGAGGTGTTAATATCAGGC
AA 
PCR for pEF13 with base 
deletion and Nco1 site 
CD1903_pBAT4_R 
ACCATGGTTAGTGGTGGTGGTGGTGGTG
TCTTTTAAACTGACGATAGC 
PCR for pEF12 and pEF13 
with His tag and Nco1 site 
EFTC_pET28a_CD6
3025970_F 
GATCCCATGGGCCTATATATATTAATAAT
AATTCTACTC 
PCR for pEF14 with Nco1 site 
EFTC_pET28a_CD6
3025970_R 
GATCCTCGAGCCTACTTTTACTTTCAAAA
AATAAAAC 
PCR for pEF14 with Xho1 site 
EFTC_pET28a_CD6
3019030_F 
GATCCCATGGGCCAAGGAGGTGTTAATA
TCAG 
PCR for pEF15 with Nco1 site 
EFTC_pET28a_CD6
3019030_R 
GATCCTCGAGTCTTTTAAACTGACGATAG PCR for pEF15 with Xho1 site 
CD2597_pCheck_L ATAGAGGTGCAGCATTTGG 
Sequencing of CD2597 
insertions 
CD2597_pCheck_R AACCTAATCGTACTCTATC 
Sequencing of CD2597 
insertions 
CD1903_pCheck_L TTTATGGGTATTGGTATTG 
Sequencing of CD1903 
insertions 
CD1903_pCheck_R TTCTGCAACAGTAAGGTAG 
Sequencing of CD1903 
insertions 
T7 Terminator TAATACGACTCACTATAGGG 
PCR screening of pET28a 
ligations 
T7 Promoter TAGTTATTGCTCAGCGGTGG 
PCR screening of pET28a 
ligations 
Table 4 Oligonucleotide primers used in this study, all 5’ to 3’ 
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2.3.1. Electrocompetent Escherichia coli 
Aliquots of E. coli DH5α, TOP10 and Rosetta2 (DE3) cultures for 
electroporation were generated by growing in 100 ml of LB to OD595 nm = 0.7 at 
37°C with shaking at 200 rpm. Cells were then harvested in 50 ml aliquots at 
3,500 rpm for 10 minutes at 4°C followed by three repeated washes in 50 ml ice 
cold 10% glycerol. Cells were finally resuspended in 1 ml ice cold 10% Glycerol, 
aliquoted to 1.5 ml Eppendorf tubes in 50 µl volumes and frozen at -80°C or 
used immediately. 
2.4. Investigation of bacterial lipoprotein signal peptidase 
proteins 
2.4.1. Sourcing of lipoprotein signal peptidase sequences 
The amino acid sequences of bacterial lipoprotein signal peptidases were 
retrieved from online repositories by conducting specific searches. For proteins 
analysed by Paetzel el al (29) or Rahman et al (177), the accession numbers 
given were used as search terms. In some cases more than one result was 
returned therefore the protein with the most similar description (gene name, 
source bacterium) to that in the literature was selected. For other proteins, such 
as those belonging to Clostridia or Myxococcus species, searches were 
conducted for the species and anticipated gene name; lspA. Amino acid 
sequences were imported into Clone Manager Professional Suite and stored for 
later use. 
2.4.2. In silico alignments of lipoprotein signal peptidase 
amino acid sequences 
To allow comparison of the amino acid sequences of lipoprotein signal 
peptidases from a variety of bacteria, amino acid sequences sourced in 2.4 
were aligned using the Align Multiple Sequences tool in Clone Manager 
Professional Suite, selecting the Multi-Way alignment type with the BLOSUM 62 
scoring matrix.  
2.4.3. Generation of WebLogo of lipoprotein signal 
peptidases 
The initial amino acid sequence alignment generated using 25 proteins as 
described in 2.4.2 was entered into the WebLogo server (199) which generated 
the output image. 
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2.4.4. Phylogenetic tree of lipoprotein signal peptidases 
A phylogenetic tree of bacterial signal peptidases was generated by selecting 
the Picture output option for the in silico alignment produced as described in 
2.4.2. The result was exported to Microsoft PowerPoint where it was modified to 
highlight proteins of interest.  
2.4.5. LspA2 BLASTp search and sequence alignment 
To identify proteins with similar sequences to C. difficile LspA, its amino acid 
sequence was entered into the BLASTp internet database search tool, choosing 
to omit any matches from C. difficile. The results were analysed and the protein 
that displayed the greatest sequence identity with the highest sequence 
coverage was selected. The amino acid sequence of this protein was imported 
into Clone Manager Professional Suite and the two proteins were aligned using 
the Compare Two Sequences tool. 
2.4.6. PSIPRED server predictions 
Predictions of the secondary structure and membrane helix topology of C. 
difficile LspA and LspA2 were performed by entering the amino acid sequences 
of each protein into the PSIPRED protein sequence analysis workbench (200), 
selecting PSIPRED v3.3 and MEMSAT3 & MEMSAT-SVM prediction methods. 
The outputs were exported as image files. 
2.5. Characterisation of growth of Clostridium difficile strains 
A scrape from a streak plate for each particular strain was inoculated into 10 ml 
sterile, pre-reduced BHI broth supplemented with antibiotics where appropriate 
and grown overnight as a start culture. 100 ml sterile pre-reduced BHI broth 
was then inoculated with 1 ml of overnight culture. At 1 hour intervals OD595 of 
the culture was measured in triplicate in a 1 cm path length plastic cuvette. 
Where required, colony forming units per millilitre (CFU ml-1) of the culture was 
determined by the technique first described by Miles and Misra (201). Briefly, a 
serial dilution of culture in PBS was performed and plated in triplicate 20 µl 
drops on agar supplemented with appropriate antibiotics; numbers of countable 
colonies were to calculate the CFU ml-1. Values were plotted graphically and 
analysed for statistical significance as described in 2.9.1. 
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2.6. Bacterial protein extractions 
2.6.1. Crude protein extractions 
Crude protein extractions of E. coli strains were prepared by mixing culture 
samples 4:1 in a screw-capped Eppendorf with SDS Sample Loading Buffer 
(41.5% v/v dH2O; 12.5% v/v 0.5 M Tris, pH6.8; 10% v/v Glycerol; 2% v/v SDS; 
5% 2-βmercaptoethanol; 0.01% bromophenol blue). Samples were then 
vortexed vigorously and boiled for 10 minutes. Finally, samples were pulsed in a 
bench-top microcentrifuge to settle cellular debris and were either used directly 
in SDS-PAGE or frozen for later analysis.   
2.6.2. Preparation of whole cell lysate and culture filtrate 
Whole cell lysates and culture filtrate samples from C. difficile strains were 
prepared as described previously (162). Briefly, the OD595 nm of 50 ml overnight 
cultures was recorded before harvesting of cells at 5,000 g for 10 minutes at 
4°C. The supernatant was retained as the culture filtrate sample. The cell pellet 
was then frozen at -20°C. Cell pellets were then thawed on ice and 
resuspended in phosphate-buffered saline (PBS) to OD595 nm = 20 based upon 
the OD of the initial culture followed by incubation at 37°C for one hour. 
Samples were either used directly in SDS-PAGE or frozen to allow later 
analysis. 
2.6.3. Low pH glycine extraction 
To prepare surface layer protein extractions of C. difficile and E. coli strains 25 
ml overnight cultures were treated as in Wright et al (202). Briefly, 25 ml of 
culture was harvested at 2,700 g for 15 minutes at 4°C then washed in 2.5 ml 
PBS followed by resuspension in 200 µl 0.2 M glycine at pH 2.2. Samples were 
then incubated at 37°C with shaking for 30 minutes before centrifugation at 
12,000 g for 15 minutes at 4°C. Supernatant was retained and neutralised with 
3.5 µl 0.25 M NaOH and either used directly in SDS-PAGE or frozen for later 
analysis. 
2.6.4. Triton X-114 Extraction 
Lipoprotein-enriched Triton X-114 extractions of C. difficile strains were 
prepared as described previously (203). Briefly, whole cell lysate samples were 
treated with pre-condensed Triton X-114 prior to freezing. Briefly, ice cold 
precondensed Triton X-114 was added to samples to a final concentration of 
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20% v/v and vortexed vigorously. This solution was then incubated on ice for 45 
minutes with frequent vortexing followed by centrifugation at 16,000 g for 15 
minutes at 4°C. The supernatant was transferred to a fresh Eppendorf tube and 
incubated at 37°C in a water bath for 10 minutes. This was then layered over an 
equal volume of warm sucrose cushion (6% sucrose w/v, 0.06% Triton X-114, 
pH 7.4) and incubated at 37°C in a water bath for 10 minutes. The sample was 
then centrifuged at 500 g for 3 minutes causing the sample to fractionate into 
three parts; the upper aqueous layer was removed and retained and the middle 
sucrose cushion layer was discarded. 9 X sample volume of ice-cold acetone 
was then added to the detergent-phase sample followed by incubation overnight 
at -20°C. Proteins were then pelleted at 16,000 g for 15 minutes at 4°C followed 
by washing with 80% v/v acetone and air drying before resuspension in 100 µl 
PBS. Samples were either used directly in SDS-PAGE or frozen for later 
analysis. 
2.7. SDS-PAGE 
To analyse the molecular weights of proteins in a sample aliquots were 
subjected to sodium dodecylsulfate – polyacrylamide gel electrophoresis (SDS-
PAGE). Unless crude protein extractions were being examined, protein 
extractions samples were mixed 4:1 in a screw-capped Eppendorf with 
NuPAGE 4X SDS Sample Buffer (Invitrogen), boiled for 10 minutes in a heating 
block and debris settled by pulsing in a bench-top microcentrifuge; crude protein 
extract samples were used directly. Initially, 15 µl of prepared samples were 
loaded into NuPAGE Bis-Tris 4 – 12% Pre-Cast gels (Life Technologies) 
alongside 5 µl of Perfect Protein Marker (Novagen) and gels were run in 
NuPAGE MES SDS Running Buffer (Life Technologies) at 150V for 40 minutes. 
To visualise protein bands, gels were stained with SimplyBlue SafeStain (Life 
Technologies) using the manufacturer’s microwave protocol followed by 
imaging using a Li-Cor Odyssey CLx platform and ImageStudio software. 
Where a sample did not produce a quality trace with good band separation and 
limited smearing, dilutions and alterations in volume were loaded.  
2.8. Hydrogen peroxide survival assays 
To assess the survival of C. difficile strains in hydrogen peroxide (H2O2), 100 ml 
overnight cultures were split according to the number of H2O2 concentrations 
being tested and individually diluted to give 20 ml of culture at OD595 nm = 0.5. 
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These cultures were then split into three 5 ml cultures, one per technical 
replicate. Colony forming units (CFU) of these untreated cultures were 
enumerated via the Miles and Misra technique (201) as described in Section 
2.5. H2O2 was then added sequentially to each culture to achieve the desired 
final concentration, allowing processing time between each aliquot to enable 
consistent timing. After 30 or 45 minutes incubation with H2O2, CFU for each 
culture were enumerated. CFU counts for cultures before addition of H2O2 
(CFUInitial) and after the implemented incubation time (CFUFinal) were used to 
calculate percent survival using the formula 
        
          
    . Results were 
combined and analysed for statistical significance using GraphPad Prism 6 
software as described in 2.9.2. 
2.9. Statistical analysis using GraphPad Prism 6 
2.9.1. Growth of strains of C. difficile 
To allow analysis of statistical difference between the growth of the tested 
strains of C. difficile it was first necessary to determine the most accurate model 
of curve fitting for the data points of each strain. This was done by comparison 
of the two most suitable models: the Exponential growth equation and the 
Sigmoidal dose-response (variable slope), anticipating the Exponential growth 
equation to be the best suited. Analysis revealed that the Sigmoidal dose-
response (variable slope) model was preferred therefore this model was applied 
to the data points. Next, the suitability of one curve for all data sets was 
assessed; if this was the case then there would be no difference between the 
data sets. This was done by posing the null hypothesis that one curve would fit 
all data sets and testing the fit using the Extra sum-of-squares F test which 
showed that a different curve for each data set was the preferred model. Finally, 
the statistical difference between all data points for a given time point was 
calculated using a two-way ANOVA test with multiple comparisons between the 
data sets of each strain using the Tukey multiple comparisons test to calculate 
confidence intervals and significance.  
2.9.2. Effect of Hydrogen Peroxide on strains of C. difficile 
To analyse the statistical differences between the percent survival of strains of 
C. difficile when subjected to different concentrations of hydrogen peroxide, 
two-way ANOVA analysis was conducted with multiple comparisons between 
49 
 
each strain using the Tukey test to calculate confidence intervals and 
significance.  
To analyse the statistical differences between the percent survival of strains of 
C. difficile at different incubation times with hydrogen peroxide, tow-way 
ANOVA analysis was conducted with multiple comparisons between the mean 
percent survival of a strain at both time periods using the Sidak test to calculate 
confidence intervals and significance. 
2.10. C. difficile CD2597 and CD1903 cloning 
2.10.1. Cloning Methodology 
The cloning methodology for generating plasmids encoding C. difficile lspA and 
lspA2 for expression in E. coli is shown in Figure 5.3. Initially an expression 
plasmid would be selected based upon its suitability for use in E. coli, allowing 
design of PCR primers to amplify each gene, with desired alterations to flanking 
regions for the inclusion of correct restriction sites and modifications of the 
gene. Once amplified, PCR products were ligated into the TA-cloning vector 
pGEM-T Easy (Promega) according to manufacturer’s instructions and 
transformed into E. coli TOP10, whereby transformants were selected for by 
blue-white selection and colony PCR confirmation. The intended protein-
encoding inserts were produced by plasmid DNA extraction from E. coli holding 
pGEM-T Easy plasmids followed by restriction digest, size selection using 
agarose gel electrophoresis and gel extraction. Expression vectors were 
digested and processed concurrently, then used in ligations which were then 
transformed into E. coli TOP10 or HB101. Once the DNA sequence of each 
plasmid had been checked for accuracy, plasmids were transformed into 
expression strains of E. coli, ready for use in protein expression experiments. 
2.10.2. Generation of plasmids 
2.10.2.1. pRL4 and pRL6 
Plasmids pRL4 and pRL6 (lspA and lspA2 in pQE80) had been previously 
generated in Dr. S. L. Michell’s laboratory at the University of Exeter by R. 
Lawrence (unpublished). 
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2.10.2.2. pEF10, pEF11, pEF12 and pEF13 
Plasmids pEF10, pEF11, pEF12 and pEF13 were generated by PCR 
amplification of C. difficile genes CD2597 (pEF10 and pEF11) and CD1903 
(pEF12 and pEF13) using the primers described in Table 4 which introduced 
Nco1 restriction sites flanking each gene, followed by conduction of the cloning 
methodology described above using pBAT4 as the expression vector. The start 
codons of each gene were modified during PCR amplification of insert 
fragments from TTG to ATG using either a 10 base insertion (pEF10 and 
pEF12) or force cloning base changes (pEF11 and pEF13) as detailed in 
APPENDIX 6. Each insert also had a C-terminus His-tag (GTG GTG GTG GTG 
GTG GTG) added during PCR amplification. Post-digestion and pre-ligation, the 
pBAT4 expression vector was treated with alkaline phosphatase (New England 
Biolabs). 
2.10.2.3. pEF14 and pEF15 
Plasmids pEF14 and pEF15 were generated by PCR amplification of C. difficile 
genes CD2597 and CD1903 respectively using the primers described in Table 
4, which introduced an upstream Nco1 restriction site and a downstream Xho1 
restriction site, followed by conduction of the cloning methodology described 
above using pET28a as the expression vector. The start codons of each gene 
were modified by overwriting base changes, mediated by the forward primers, 
during PCR amplification from TTG to ATG GGC.  
2.10.3. Bacterial DNA extractions 
2.10.3.1. Preparation of plasmid DNA via minipreps 
Plasmid DNA from strains of E. coli was extracted using either the QIAprep Spin 
Miniprep kit (Qiagen) or the PureYield Plasmid Midiprep System (Promega) 
depending on the desired output volume and concentration according to the 
manufacturers’ instructions. 
2.10.3.2. Preparation of DNA boilates for colony PCR 
To allow rapid assessment of plasmid transformation success, antibiotic-
resistant colonies were picked and suspended in 100 µl sterile nuclease-free 
deionised water (Life Technologies), followed by streaking as individual colonies 
to selective grid plates. Suspensions were then boiled in a heating block 
followed by pelleting of cellular debris in a bench-top microcentrifuge. 
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Supernatant was then used as template DNA in PCR reactions designed to 
amplify fragments specific to the transformed plasmid. 
2.10.4. Polymerase chain reaction conditions 
Table 5 shows the PCR cycle conditions used in this study. 
Table 5 Polymerase chain reaction cycle conditions 
Reaction Step Temperature Time Cycles 
    
Enzyme activation 95 °C 10’  
Denaturation 94 °C 1’ 
35 Primer Annealing 56 °C 1’ 30” 
Extension 72 °C 4’ 
Final Extension 72 °C 10’  
Hold 4 °C ∞  
    
 
All PCRs were performed using HotStarTaq DNA Polymerase (Quiagen) with 
associated 10X PCR Buffer and PCR Grade dNTP Mix. Each reaction used 
constituents in the proportions shown in Table 6, prepared as a master mix of 
all except DNA template in a quantity suitable for 1.1 times the number of 
reactions to be performed.  
Table 6 Polymerase chain reaction constituents 
Constituent Volume (µl) 
for 10 µl total 
  
Forward primer (20 mM) 1 
Reverse primer (20 mM) 1 
10X PCR Buffer 1 
dNTPs (10 mM) 0.5 
HotStarTaq 0.1 
Nuclease-free water 3.4 
DNA template / 
nuclease-free water 
3 
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2.10.5. DNA digestion by restriction endonucleases 
Digestion of DNA samples was performed using restriction endonucleases 
supplied by New England Biosciences according to the manufacturer’s 
specifications. Briefly, 10 µl of DNA sample was mixed with 1 µl of each enzyme 
selected, 1.5 µl appropriate enzyme buffer and made up to 15 µl with nuclease-
free water. Reactions were mixed thoroughly then incubated at 37 °C before 
inactivation of the enzymes at manufacturer-advised temperatures. For 
preparatory digests to produce large quantities of DNA fragments for cloning the 
reaction volume was increased to 80 µl by mixing 42.5 µl DNA sample, 4 µl of 
each selected enzyme, 8 µl of appropriate enzyme buffer and made up to the 
total volume with nuclease free water. These reactions were incubated at 37 °C 
for at least one hour to allow complete digestion followed by heat-inactivation. 
2.10.6. Agarose gel electrophoresis 
To allow size selection of DNA samples for analysis of either PCR products or 
restriction digest products, samples were mixed 1:5 with 6X DNA Loading Dye 
(Thermo Scientific) and loaded into 1 % w/v Agarose (Melford) in Tris-acetate-
EDTA buffer. Gel electrophoresis was typically performed at 120 V until loading 
dye bands had reached past halfway across the gel or at 90 V for size selection 
of preparatory DNA digests. DNA markers were included for fragment size 
comparison: 1 kb Plus DNA ladder and 100 bp plus DNA ladder (Thermo 
Scientific) 
2.10.7. Ligation of DNA fragments 
Ligations of DNA fragments except those performed with pGEM-T Easy were 
performed with T4 DNA Ligase (New England Biolabs) according to the 
manufacturer’s specifications. Briefly, reaction mixes including controls were 
prepared according to Table 7 and incubated overnight at 16°C in a heating 
block. Volumes of cut vector (x) and cut insert (y) were calculated according to 
the formulae displayed in the table, assuming an ideal ratio of 1:3 and reaction 
concentrations of 50 fmol vector and 150 fmol insert. DNA concentrations in 
samples were determined by analysis using a Nanodrop 1000 (Thermo 
Scientific). 
 
 
53 
 
Table 7 Ligation reaction mixes and volume calculations 
Reaction Cut 
Vector 
(µl) 
Cut 
Insert 
(µl) 
10X T4 
DNA ligase 
buffer (µl) 
T4 DNA 
ligase 
(µl) 
Nuclease-
free water 
(µl) 
Total 
volume 
(µl) 
       
Control x 0 3 1 To Total 30 
Ligation x y 3 1 To Total 30 
       
       
                                 (  )        
                                 (  )        
                (  )   
           
              (
  
  
)
 
       
 
2.10.8. Transformation of plasmids into bacteria 
2.10.8.1. Heat Shock 
Plasmid DNA was transformed into chemically competent E. coli by heat shock. 
Briefly, one 200 µl aliquot of competent cells per sample was thawed on ice. 10 
µl of DNA sample was then added to the cells and gently mixed before 
incubation on ice for 30 minutes. Samples were then heat shocked at 42°C for 
30 – 60 seconds before further incubation on ice for 10 minutes. 1 ml pre-
warmed LB broth was then added to samples which were then incubated at 
37°C for one hour with shaking. Samples were then plated to LB agar 
supplemented with appropriate antibiotics in multiple 100 µl aliquots before 
incubation overnight at 37°C. 
2.10.8.2. Electroporation 
Plasmid DNA was transformed into electro-competent E. coli by electroporation. 
Briefly, one 50 µl aliquot of competent cells per sample was thawed on ice while 
6 – 10 µl DNA samples were dialysed on nitrocellulose membranes (Millipore) 
over 20 ml of deionised water for 30 minutes. DNA samples were then added to 
the competent cells and mixed gently. Samples were then transferred to the 
bottom of 0.2 cm electroporation cuvettes (Bio-Rad) followed by pulsing in a 
Bio-Rad MicroPulser Electroporator set to Bacteria Ec2. Cells were then 
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washed from the cuvette by five repeated flushings with 200 µl pre-warmed LB. 
Flushings were pooled for each sample and incubated in an Eppendorf tube at 
37°C for one hour with shaking. Finally, samples were serially diluted to 10 -5 
and 100 µl aliquots spread plated to LB agar supplemented with appropriate 
antibiotics and incubated overnight at 37°C. 
2.10.9. DNA sequencing and analysis 
To determine the DNA sequence of a region of a plasmid, samples of Miniprep 
elutions were sent for Sanger Sequencing by Source BioScience. The DNA 
concentration of Miniprep elutions was measured by analysis using a Nanodrop 
1000 (Thermo Scientific) and adjusted to 100 ng µl-1 as per sample 
specifications. Sequencing runs were either performed with stock primers or 
specific primers were designed and provided at a concentration of 3.2 pmol µl-1. 
DNA sequence files were analysed using Clone Manager Professional Suite.  
2.10.10. Rare Codon Caltor analysis of C. difficile CD1903 
and CD2597 
To determine the rare codon usage within C. difficile genes CD2597 and 
CD1903 the DNA sequences of each gene was entered into the Rare Codon 
Caltor (204) internet form for analysis. 
2.11. IPTG induction of protein expression 
Expression of proteins cloned into expression vectors containing T7lac 
promoters in suitable E. coli strains was initially conducted using Isopropyl β-
D1-thiogalactopyranoside (IPTG). Overnight cultures of strains were used to 
provide 250 µl inoculums which were added to 10 ml pre-warmed LB broth 
containing appropriate antibiotics. These cultures were then incubated at 37 °C 
with shaking until the OD595 nm reached between 0.6 and 1. 800 µl was removed 
and preserved as a non-induced sample. IPTG was added to the remainder to a 
final concentration of 1 mM. After 3 hours further incubation, 800 µl induced 
samples were taken and prepared for SDS-PAGE analysis. 
2.12. Auto-induction of protein expression 
Protein expression was auto-induced following the protocol set out in Studier, 
2005 (205). The general compositions of the media used are given in Table 8 
and the composition of specific solutions as follows: 50X “M” solution: 1.25 M 
Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M Na2SO4; 50X “5052” solution: 
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25 % (v/v) glycerol, 2.5 % (w/v) glucose, 10 % (w/v) α-lactose monohydrate; 
100X “505” solution: as for “5052” solution with no α-lactose monohydrate. 
1000X Trace Metals solution was prepared as follows: 20 mM CaCl2, 10 mM 
MnCl2, 10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2.2H2O, 2 mM NiSO4.6H2O, 2 
mM Na2MoO4.2H2O, 2 mM Na2SeO3, 2mM H3BO3 made up with water and 
autoclaved plus 50 mM FeCl3.6H2O made up in 1 ml concentrated HCl and 100 
ml water before filter-sterilization. Briefly, E. coli strains for the experiment were 
grown overnight at 37°C and 200 rpm shaking in MDG media supplemented 
with the appropriate antibiotics, typically 100 µg ml-1Ampicillin.1 ml of overnight 
culture was then inoculated to 150 ml or 100 ml respectively of ZYM-5052 and 
ZYM-505 media. These cultures were then grown for 48 hours at 20°C and 300 
rpm shaking. MDG media is a minimal media suitable for growing working 
stocks, ZYM-505 media is suitable for the growth of high-density cultures (non-
induced samples) and ZYM-5052 media is suitable for the growth of high-
density cultures and is auto-inducing due to the presence of α-lactose 
monohydrate in the “5052” solution (auto-induced samples). 
2.13. Western Blotting 
To demonstrate that His-tagged proteins were present in DNA samples that had 
been subjected to SDS-PAGE analysis, non-stained SDS-PAGE gels were 
blotted to nitrocellulose membranes in iBlot Transfer Stacks (Invitrogen) using 
the iBlot system (Invitrogen). Membranes were then stained by washing with 
Ponceau-S stain (0.1% w/v Ponceau-S in 5% v/v galacial acetic acid) to confirm 
transfer of proteins. The Ponceau-S stain was removed by washing with 0.1 M 
sodium hydroxide and deionised water. Membranes were then blocked in tris 
buffered saline with 1% Tween 20 (TBS-T) 5% w/v skim milk powder at 4°C 
overnight. Next, membranes were washed three times in TBS-T with room 
temperature incubation with shaking for 10 minutes between each wash. His-
Tag monoclonal antibody HRP-conjugate (Novagen) was diluted 1:4,000 in 
TBS-T plus 3% w/v skim milk powder; this solution was made up to a 10 ml 
volume and poured over the membrane before incubation for one hour at room 
temperature. Membranes were then washed three times in TBS-T before 
developing using 200 µl each of Lumigo Reagent A and Peroxide Reagent B 
(Cell Signalling Technology) made up to 4 ml with deionised water then poured 
over the membrane before 5 minutes incubation. Membranes were then 
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wrapped in cling film and imaged by chemiluminescence illumination and 
sequential imaging using a Bio-Rad ChemiDoc XRS+ System and ImageLab 
software. 
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  Media 
Tryptone 
(g) 
Yeast 
Extract 
(g) 
De-
mineralised 
Water (ml) 
60X “M” 
Solution 
(ml) 
100X “505” 
Solution 
(ml) 
50X 
“5052” 
Solution 
(ml) 
2 M 
MgSO4 
(ml) 
1000X 
Trace 
Metals 
Solution 
(µl) 
40% (w/v) 
Glucose 
(ml) 
5% (w/v) L-
Aspartate 
Solution 
(ml) 
           
MDG   920 20   1 200 12.5 50 
ZYM-505 10 5 970 20 10  1 200   
ZYM-5052 10 5 960 20  20 1 200   
           
Table 8 Media composition for auto-induction of protein expression. 
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Chapter 3. Bioinformatic analysis of lipoprotein signal 
peptidases in bacteria 
3.1. Introduction 
To date, few species of bacteria have been shown to contain two versions of a 
lipoprotein signal peptidase gene; while both CD2597 and CD1907 may be 
putative lipoprotein signal peptidases in C. difficile. Both genes are shown to be 
functional later herein and in previous work using strains of C. difficile 630 
mutated for each gene, with very similar behaviour which may indicate a similar 
function. Much can be elucidated about the function of a protein from its 
primary, secondary and tertiary structures, from the sequence location of 
functional amino acids to the presence of structural domains. There is 
considerable evidence of a conserved tertiary structure and membrane topology 
within lipoprotein signal peptidases in conjunction with conserved domains 
containing functional amino acids (29, 30, 177, 178); these properties may be 
used to indicate the functionality of a putative lipoprotein signal peptidase. 
This chapter aims to show the properties of C. difficile 630 LspA (CD2597) and 
LspA2 (CD1903) elucidated through a selection of bioinformatics analyses. 
These analyses include amino acid sequence comparison to known lipoprotein 
signal peptidases to find conserved domains, the similarity between LspA and 
LspA2 and of LspA2 to other lipoprotein signal peptidases. 
3.2. Multiple alignment of annotated lipoprotein signal peptidase 
genes 
The amino acid sequences of twenty five annotated lipoprotein signal peptidase 
proteins, including both LspA and LspA2 from C. difficile 630 were aligned using 
the Align Multiple Sequences tool in Clone Manager Professional Suite. These 
genes were selected from those used in similar alignments in  Rahman et al 
(177) and Paetzel et al (29) where the same gene sequence was available in 
online repositories with the addition of LspAs from some Clostridia and the four 
LspAs from Myxococcus xanthus. The initial alignment with protein accession 
numbers is shown at APPENDIX 1 and includes indication of the location of the 
5 conserved amino acid sequence homology domains A through E with regions 
of homology highlighted in green. This alignment shows that all of the genes 
selected contain all of the expected domains. There are regions of significant 
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variation outside of these domains. A second alignment was therefore 
performed which included as many Gram positive lipoprotein signal peptidase 
proteins from Paetzel et al (29) and Rahman et al (177) as possible. This 
alignment was entered into the WebLogo 3.3 tool (199) to produce Figure 3.1, 
in which the conserved domains have again been identified. Here, the domains 
are made much clearer by the greater frequency of the expected amino acids in 
each domain, as represented by the larger letter at the given position. Both of 
these views of the alignments support the evidence that lipoprotein signal 
peptidases contain these 5 conserved amino acid sequence domains and they 
show that both LspA and LspA2 in C. difficile 630 contain them. The highly 
represented amino acids in the sequence alignment (APPENDIX 1) and the 
WebLogo (Figure 3.1) were then used to produce consensus sequences for 
each conserved amino acid domain (Table 9), allowing comparison to the 
sequences shown in Table 1. 
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The WebLogo 3.3 tool (199) was used to generate a representative image of 
the amino acid sequences of twenty five lipoprotein signal peptidase genes from 
a variety of bacteria. Relative amino acid frequency at each locus is 
represented by letter height. The conserved amino acid sequence domains 
reported in Rahman et al (177) and Paetzel et al (29) are clearly demonstrated  
as regions with several amino acids at high relative frequencies and are 
identified in boxes, using the nomenclature A through E. 
Figure 3.1 WebLogo of aligned lipoprotein signal peptidase from various 
bacteria, highlighting the conserved functional amino acids 
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Table 9 Comparison of the expected amino acid sequences of lipoprotein 
signal peptidase conserved domains given in the literature (Figure 1.4 and 
Table 1) to the sequences generated in this study showing considerable 
similarities 
The conserved domain sequences for lipoprotein signal peptidases shown in 
Table 1 are presented alongside those derived in this study. Comparison of the 
domain sequences shows considerable similarity, with most differences arising 
in amino acid relative frequencies. The relative frequency of each amino acid in 
consensus sequences is denoted by the type of lettering: uppercase indicates a 
very high frequency; lowercase indicates a low frequency and ‘x’ indicates no 
evidence of conservation at that residue. Amino acid frequency or level of 
conservation was not analysed by Rahman et al (177). 
Domain 
Tjalsma et al 
(30) 
Paetzel et al 
(29) 
Rahman et al 
(177) 
This study 
     
A dqxxk dxxtk DQLSK DqxxK 
B NxGaaf NxGaaf NYGISF NxGaaF 
C ixggalgNxxDr iiggaxIgNxxDr VIGGAVGNLIDR iigGalGNxxxDR 
D VvD vvd VFD VvDf 
E FNxAD FNxAD FNLAD FNxAD 
     
 
 
3.3. Phylogenetic tree of lipoprotein signal peptidases 
The Align Multiple Sequences tool was then used, with the second alignment 
produced in Section 3.1, to produce a phylogenetic tree, shown in Figure 3.2; 
the protein accession numbers are shown in APPENDIX 2. Lipoprotein signal 
peptidase genes from either the same species or species from the same genus 
cluster together, indicating that they are more similar to each other than to the 
genes from the other bacteria. This suggests that the regions of variation 
outside of the domains and the variation within them may be associated with the 
source species or genus. Of particular note however, is that the C. difficile 630 
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LspA2 sequence does not group to the same sub-clade or even clade as the 
sequences of C. difficile 630 LspA or other Clostridia. In fact, it does not appear 
to group with any of the other genes in the alignment. This indicates that this 
gene may have origins in a species of bacteria whose lipoprotein signal 
peptidase proteins have not been investigated here.  
3.4. Potential sources of LspA2 
Because the amino acid sequence of LspA2 shares very little homology to any 
of the lipoprotein signal peptidases used in the alignment and phylogenetic tree, 
this sequence was entered into the BLASTp internet-based tool and the 
database of protein sequences was searched excluding proteins from C. 
difficile. The results demonstrate that the two most similar protein sequences in 
the database belong to unclassified Lachnospiraceae bacterium, which also 
belong to the order Clostridiales. Both of these proteins are annotated as 
peptidase A8 with either 73% identity at 80% coverage or 96% at 61% 
coverage. An amino acid sequence alignment of the result (80% coverage) to 
LspA2 reveals many amino acid differences and similar conserved domain 
sequences, except domain A which does not appear in the peptidase A8 
sequence. The top 10 BLASTp results and the amino acid sequence alignment 
of LspA2 and peptidase A8 are shown in Figure 3.3. 
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Figure 3.2 Phylogenetic tree of lipoprotein signal peptidase genes from 
various bacteria 
An alignment of the amino acid sequences of twenty five lipoprotein signal 
peptidases from a variety of bacteria was generated and processed in Clone 
Manager Professional Suite to produce a phylogenetic tree of these proteins. 
Proteins from a single bacteria or from bacteria in the same genus group 
together into apparent clades, as demonstrated by the highlighted groups; 
Myxococcus xanthus (orange), Clostridium spp. (blue plus C. difficile 630 LspA 
in red) and Rickettsia spp. (green) however C. difficile 630 LspA2 (red, top) 
does not group into any clade and notable does not group with C. difficile 630 
LspA. 
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Figure 3.3 Amino acid sequence alignment of C. difficile 630 LspA2 
(CD1903) to peptidase A8 from Lachnospiraceae bacterium 
Amino acid sequence alignment of the peptidase A8 from Lachnospiraceae 
bacterium, the top hit from a BLASTp search for C. difficile 630 LspA2 (CD1903) 
to LspA2 with non-matching amino acids highlighted in orange. 
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3.5. Analysis of the predicted structures of LspA and LspA2 in C. 
difficile 
As discussed in Section 1.7 and shown in Figure 1.4, there is a particular 
structure associated with lipoprotein signal peptidases which includes 4 
transmembrane domains and a particular localisation of the 5 conserved 
domains. To investigate whether this was the case for LspA and LspA2 in C. 
difficile 630, the amino acid sequences of each gene were entered into the 
PSIPRED server (200) using the secondary structure and membrane topology 
(MEMSAT3) prediction methods as described in Materials and Methods, with 
the results displayed in Figure 3.4. These predictions demonstrate with high 
confidence that both proteins possess the expected 4 transmembrane domains, 
composed of helices. Further, they show that the 5 conserved sequence 
domains, the positions of which have been overlaid on the figure based upon 
the annotated amino acid positions, are located very similarly to the model 
structure presented in Figure 1.4 and Paetzel et al (29). There are noticeable 
differences in the predicted secondary structures of the two proteins however, 
with different lengths of protein between the transmembrane helices and 
different predicted helix lengths. 
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The amino acid sequences of C. difficile 630 LspA (CD2597) [A and C] and 
LspA2 (CD1903) [B and D] were entered into the PSIPRED server (200), 
returning these results. A and B: domain prediction output, indicating the 
positions of regions predicted to have helical, strand or coil secondary 
structures with the confidence of each prediction displayed. C and D: output 
from the MEMSAT3 prediction, indicating the membrane helix prediction for 
each protein, partially revealing the potential tertiary structure of both proteins. 
The annotated amino acid positions were used to overlay the positions of the 5 
lipoprotein signal peptidase conserved domains, A through E, revealing that 
their positions in the structures is very similar to the general representation in 
Paetzel et al (29) with minor differences in specific localisations between the 
two proteins. 
Figure 3.4 Domain predictions for both copies of lipoprotein signal 
peptidase in C. difficile 630 
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3.6. Discussion 
The two lipoprotein signal peptidases encoded in the C. difficile 630 genome 
share a number of common features. Both proteins contain the 5 expected 
amino acid domains that have been shown to be common to many lipoprotein 
signal peptidases from other species of bacteria (29, 30, 177), indicating their 
function and functionality. These conserved domains do differ in sequence 
between the two strains however the key amino acids that identify each domain 
are mostly present in both proteins with greater variation in LspA2 compared to 
the expected sequence. This variation does not extend to the two aspartic acid 
residues that are thought to for the active site of the proteins in domains C and 
E. Variation within the domains and in the regions between them is common 
across lipoprotein signal peptidases from other species of bacteria and such 
variations may allow grouping of bacteria. The amino acid sequences of 
lipoprotein signal peptidases from the same bacteria or from bacteria within the 
same genus appear to group together in clades however, LspA2 does not group 
with LspA or with proteins from other Clostridia, suggesting that LspA2 has a 
different origin to LspA. To briefly investigate this origin, a BLASTp search for 
the amino acid sequence of LspA2 was conducted, revealing that the most 
similar protein in the database is peptidase A8 from an uncharacterised 
Lachnospiraceae bacterium. This genus of bacteria belongs to the same 
taxonomic order (Clostridiales) as C. difficile, and it may be possible that C. 
difficile picked up the lspA2 gene from this genus. The presence of multiple 
differences between the two amino acid sequences indicates that any genetic 
transfer between the two host species occurred a long time ago and no further 
conclusions can be drawn. As such, more work could be conducted to examine 
the origin of LspA2. Analysis of the predicted secondary and tertiary structures 
of LspA and LspA2 using the PSIPRED (200) server demonstrates that both 
proteins possess the expected four transmembrane helices and general 
configuration. Further, the 5 conserved domains are present at locations that 
are very similar to those in the model type II signal peptidase displayed in 
Figure 1.4, suggesting that both proteins could be functional in the expected 
fashion. Both LspA and LspA2 possess the expected features of lipoprotein 
signal peptidases and LspA2 may have an origin in other bacteria.  
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Chapter 4. Phenotypic characterisation of C. difficile 
strains defective in lipoprotein biosynthesis and 
analysis of their response to antimicrobial stresses 
4.1. Introduction 
C. difficile strains have been generated that are mutants in CD2597 (lspA) and 
CD1903 (lspA2) (34-36), named ECF1 and ECF2 respectively, to allow 
investigation of the roles that the two functional versions of lipoprotein signal 
peptidase encoded by these genes play in C. difficile. The strains were shown 
to have very similar growth characteristics to the 630Δerm wild type however 
ECF1 was shown to have a different protein profile to both the wild type and 
ECF2, with other variations seen in ECF2. The ability of each strain to withstand 
oxidative stress was examined, and it was shown that ECF1 was significantly 
less susceptible than the wild type and ECF2 behaving similarly but less 
significantly. Further work will be required in this area to demonstrate why 
disruption of lipoprotein biosynthesis appears to be beneficial to the mutant 
strains and to further investigate the effect of incubation time on survival.  
4.2. C. difficile strains defective in lipoprotein biosynthesis 
In previous work, two C. difficile strains were generated that were defective in 
lipoprotein biosynthesis by using the ClosTron system to knock out the lspA and 
lspA2 genes, creating strains ECF1 and ECF2 respectively, with each strain 
subsequently shown to differ from the wild type in tolerance to malachite green 
(34, 35). The plasmids used to generate these knockout strains are shown in 
APPENDIX 3. Confirmation of the presence of mutations in these strains was 
performed by PCR on genomic DNA extractions. These PCRs used primers 
which flanked the intron insertion site or which bind within the intron and are 
shown in Figure 4.1 and confirmed that both strains were correct mutants. 
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PCRs to confirm the generation of ClosTron mutants in C. difficile 630 of lspA 
(CD2597) and lspA2 (CD1903). A: CD1903, left gel: insertion site flanking 
primers, middle gel: intron Ram primer pair, right gel: forward flanking primer 
with intron EBS universal primer. All gels lane 1: C. difficile ECF2 (CD1903 
mutant), lane 2: C. difficile 630Δerm. B: CD2597, left gel: flanking primers, right 
gel: intron Ram primer pair. All gels lane 1: C. difficile ECF1 (CD2597 mutant), 
lane 2: C. difficile 630Δerm. The difference in band sizes with flanking primers 
for both genes indicates the presence of the intron within the gene, as does the 
presence of a band with the intron Ram primers. PCR with the forward flanking 
primer and the intron EBS universal primer was necessary for the CD1903 
mutant because of the double band with the flanking primers, and the presence 
of a band indicates the presence of the intron in the insertion site. Figure 
adapted from Farries, 2012 (34). 
Figure 4.1 PCR confirmation of ClosTron mutants in lspA and lspA2 of C. 
difficile 
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4.3. Analysis of the growth of C. difficile strains 
To investigate if the mutations in C. difficile strains ECF1 and ECF2 had a 
pleiotropic effect on growth of the strains, their growth was assayed alongside 
the C. difficile 630Δerm wild type strain by measuring the optical density of 
cultures at one hour intervals. The results of triplicate growth curves were 
combined and plotted using GraphPad Prism 6, which also allowed statistical 
analysis of the curves; the results are shown in Figure 4.2 and the statistical 
analysis is shown in APPENDIX 4. It was observed that, at 5h and 6h, 630Δerm 
had a significantly different average optical density to ECF1 (P=0.0251, 
P=0.0223) but not ECF2 (P=0.2581, P=0.1212). This is reflected in the graph 
with the fitted curve for 630Δerm appearing higher than the other two curves, 
particularly at these two time points. Despite this difference, all three strains 
appear to enter exponential growth after a very similar lag phase, followed by 
growth at a very similar rate, entering stationary growth after a very similar time 
period. 
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Figure 4.2 Growth curves of wild type and lspA mutant strains of C. 
difficile 
Overnight cultures of C. difficile strains 630Δerm (   ), ECF1 (   ) and ECF2 (   ) 
were used to inoculate fresh media which was then monitored for growth by 
measuring the optical density at 595 nm every hour up to 12 hours. The 
experiment was performed in triplicate and the results collated in GraphPad 
Prism 6 which allowed statistical analysis. This analysis allowed plotting of best 
fit curves for each strain using a Sigmoidal dose-response model and it was 
found that one curve would not be suitable for all three data sets. Further 
analysis revealed that the OD595 nm for 630Δerm at 5 h and 6 h was significantly 
different to that of ECF1 however the remainder of the data points were 
statistically similar across all three strains. Error bars represent standard 
deviation of the triplicate results. 
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4.4. Protein profiles of C. difficile strains 
Using the extraction protocols defined in Materials and Methods, the protein 
profiles of C. difficile strains 630Δerm, ECF1, ECF2 and 630ΔermΔlgt were 
investigated to examine whether there are any observable differences in 
lipoprotein processing between the strains. Lipoproteins that have not 
undergone signal peptide cleavage by LspA or LspA2 may be observably 
larger, resulting in the shift of a protein band between strains. Initially, the whole 
cell lysate and culture filtrate for the first three strains were compared by SDS-
PAGE of prepared samples, as shown in Figure 4.3.A, to look for evidence of 
additional proteins being released to the culture filtrate in the two mutant strains. 
It was hypothesised that the lipoprotein signal peptidase mutants would be less 
able to anchor proteins to the cell than the wild type due to the disruption to 
lipoprotein maturation, causing release of lipoproteins into the culture filtrate. In 
this case, no such differences are directly apparent; in particular comparing 
strains 630Δerm to ECF2 (Figure 4.3.A lanes 1 and 3) where all bands are 
present in both lanes. Strain ECF1 (Lane 2) may have some differences 
however all bands are present with some relative intensity changes. A protein 
that is present in one fraction but not the other will correspond to a band at a 
particular molecular weight that is only visible in one fraction. As such, where a 
band is visible for one strain but not the others in that fraction, a protein may be 
localised differently between those strains. Figure 4.3.A, Culture Filtrate Lanes 
1 and 3 show a clear band at approximately 26 kDa which is not as strongly 
present in Lane 2. No such band is visible in Lane 2 for the Whole Cell Lysate 
samples, suggesting that the protein represented by the band is not found in 
either fraction for ECF1. This protein may be localised to another cellular 
fraction or it may be differentially expressed in this strain.  
It was then considered that incorrectly processed lipoproteins may remain 
associated with the cell wall due to incomplete processing, instead of the culture 
filtrate in the mutant strains. Therefore, extractions that enrich for the outer 
layers of the cell were performed for strains 630Δerm, ECF1 and ECF2. The 
TX-114 extraction, which enriches for lipoproteins (203), was also performed for 
the 630ΔermΔlgt strain. Samples were run through SDS-PAGE as shown in 
Figure 4.3.B. In the low pH glycine extraction, which removes proteins 
associated with the C. difficile cell wall (202), one band at approximately 24 kDa 
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in the ECF1 lane (Lane 2) is distinctly darker than the bands for the other 
strains at the same molecular weight. Further, a band at the same molecular 
weight does not appear in Lane 2 but does appear in Lanes 1 and 3 and other 
bands visible in Lane 2 of the low pH Glycine extraction at approximately 15 
kDa are not visible in Lanes 1 and 3 for the same extractions but may be visible 
in Lanes 1 and 3 for the detergent phase of the TX-114 extraction. This 
suggests that the proteins in this band are being located differently in the 
corresponding strain, ECF1. There are other differences between the two 
phases of the TX-114 extraction with various bands appearing at different 
intensities between strains though nothing as distinct as that seen with the low 
pH glycine extraction for ECF1 when compared to each other and to 630Δerm. 
There are however, more intensity differences when the TX-114 extraction of 
the 630ΔermΔlgt strain (Lane 4) is compared to similar extractions of the other 
strains, supporting previous observations that protein processing is 
considerably different in this strain compared to 630Δerm.  
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Figure 4.3 SDS-PAGE of protein extractions from C. difficile 630Δerm, 
ECF1, ECF2 and 630ΔermΔlgt 
To examine the possibility that incorrectly processed lipoproteins would locate to 
different parts of the cell, protein extractions were performed on C. difficile 
630Δerm (Lane 1), ECF1 (Lane 2), ECF2 (Lane 3) and 630ΔermΔlgt (Lane 4) 
where relevant. A: Initially, it was thought that incorrectly processed lipoproteins 
would be released from the cell, therefore the whole cell lysate and culture 
filtrate were analysed by SDS-PAGE to look for protein bands that were 
arranged differently in each strain; no major differences were observed. B: 
Protein extractions that correctly processed lipoproteins may locate to were then 
examined, including the lipoprotein-enriching TX-114 extraction. 630ΔermΔlgt 
was also examined here. A band at approximately 24 kDa appears much 
brighter in a low pH glycine extraction of ECF1 (arrow) with other bands 
appearing at varying intensities in both extractions. 
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4.5. Response to hydrogen peroxide oxidative stress 
4.5.1. Initial analysis 
To investigate the effect of disruption of lipoprotein biosynthesis on the 
resistance of C. difficile to oxidative stress, broth cultures of 630Δerm, ECF1 
and ECF2 were treated with hydrogen peroxide for 30 minutes at a variety of 
concentrations, ranging from 0 mM as a control to 1 mM H2O2. Colony forming 
units for each strain were enumerated before and after addition of hydrogen 
peroxide, allowing calculation of percent survival. As can be seen in Figure 4.4, 
there was a general reduction in % survival for all strains with increasing 
hydrogen peroxide concentration ([H2O2]), particularly with the higher 
concentrations used. It was observed that there was a higher % survival of both 
ECF1 and ECF2 compared to the 630Δerm wild type at 0.1 mM and no 
measurable growth for any strain at 1 mM. Statistical analysis was conducted 
using GraphPad Prism 6 using a two-way ANOVA followed by Tukey’s multiple 
comparisons test to determine the significance of any differences in % survival 
between strains at each concentration. The details of this analysis can be found 
at APPENDIX 5, and the results are portrayed above the graph. There was 
statistically significant variation between ECF1 and ECF2 at 0.01 mM 
(P=0.0127) and between 630Δerm and ECF1 at 0.05 mM (P=0.0178).  It was 
expected that the % survival of each strain would decrease as the hydrogen 
peroxide concentration increased; the 630Δerm strain does not appear to follow 
this trend between 0 and 0.05 mM H2O2,indicating that the significant difference 
between 630Δerm and ECF1 at 0.05 mM may be due to experimental variation. 
At 0.1 mM, both ECF1 and ECF2 were significantly different to 630Δerm 
(P=0.0012, P=0.0002), and both mutant strains appeared similarly better able to 
survive the imposed stress. 
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Figure 4.4 Effect of hydrogen peroxide concentration on survival of C. 
difficile strains 
Broth cultures of C. difficile 630Δerm (black bars), ECF1 (light grey bars) and 
ECF2 (dark grey bars) were treated with hydrogen peroxide (H2O2) at 
concentrations of 0, 0.01, 0.05, 0.1 and 1 mM for 30 minutes with three 
experimental and three technical replicates. Percent survival was calculated 
from colony forming units per millilitre of culture before and at the end of 
treatment, calculated via the Miles and Misra method. Statistical analysis was 
conducted in GraphPad Prism 6: error bars represent standard deviation; stars 
indicate the statistical difference between the bars indicated by the ends of the 
brackets. P-values: * ≤ 0.05; ** ≤ 0.01; *** ≤ 0.001. 
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To further analyse the effect of [H2O2] on these three strains, a concentration 
that would allow zooming in on the point where % survival drops to zero was 
selected that lay between the two concentrations that demonstrated this effect 
in the previous assay. Thus, the assay was performed using concentrations of 
0.1, 0.5 and 1 mM with the results treated the same as previously and displayed 
in Figure 4.5. In this case, the statistical analysis (APPENDIX 5) reveals 
significant variation between the wild type and ECF1 at 0.1 mM H2O2 
(P=0.0015). The % survival of the ECF1 strain does not decrease as expected 
between 0.1 and 0.5 mM; experimental variation may have resulted in the value 
at 0.1 mM being lower than expected. At 0.5 mM H2O2, it is very clear that 
ECF1 has a significantly higher % survival than the other two strains 
(P630=0.0006, PECF2=0.0006). 
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Figure 4.5 Further investigation of the effect of hydrogen peroxide 
concentration on survival of C. difficile strains 
To further investigate the effect of hydrogen peroxide on C. difficile 630Δerm 
(black bars), ECF1 (light grey bars) and ECF2 (dark grey bars), broth cultures of 
these strains were treated with 0.1, 0.5 or 1 mM hydrogen peroxide for 30 
minutes in three experimental replicates with three technical replicates. Percent 
survival was calculated from colony forming units per millilitre of culture before 
and at the end of treatment, calculated via the Miles and Misra method. 
Statistical analysis was conducted in GraphPad Prism 6: error bars represent 
standard deviation; stars indicate the statistical difference between the bars 
indicated by the ends of the brackets. P-values: ** ≤ 0.01; ** ≤ 0.001. 
  
79 
 
4.5.2. Effect of incubation time with hydrogen peroxide 
It was hypothesised that there may be a difference in response to incubation 
with hydrogen peroxide over time. To investigate this, 630Δerm, ECF1 and 
ECF2 were incubated for either 30 or 45 minutes in 1 mM H2O2, with % survival 
calculated as before, with results in Figure 4.6. It was observed that there was 
an increase in % survival for all three strains at 45 minutes compared to 30 
minutes however statistical analysis with GraphPad Prism 6 (APPENDIX 5) 
revealed that this was only statistically significant for ECF1 (P=0.0065) and 
ECF2 (P=0.0215), indicating their greater ability to survive in the presence of 
hydrogen peroxide when compared to the wild type. 
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Figure 4.6 Effect of incubation time with hydrogen peroxide on survival of 
C. difficile strains 
To find the effect of incubation time during hydrogen peroxide treatment on the 
survival of C. difficile 630Δerm (black bars), ECF1 (light grey bars) and ECF2 
(dark grey bars), broth cultures were treated with 1 mM hydrogen peroxide for 
30 minutes or 45 minutes in three experimental replicates with three technical 
replicates. Percent survival was calculated from colony forming units per 
millilitre of culture before and at the end of treatment, calculated via the Miles 
and Misra method. Statistical analysis was conducted in GraphPad Prism 6: 
error bars represent standard deviation; stars indicate the statistical difference 
between the bars indicated by the ends of the brackets; the difference between 
% survival of a given strain at each time period. P-values: * ≤ 0.05; ** ≤ 0.01. 
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4.6. Discussion 
The C. difficile mutant strains ECF1 and ECF2 have been shown to be 
phenotypically different to the C. difficile 630Δerm wild type. Firstly, PCR 
analysis of genomic DNA from each strain was used to confirm the providence 
of the mutants by demonstration of the insertion of the Group 2 intron. To check 
that neither mutation had a pleiotropic effect upon the growth of the strain, 
growth curves for each were generated. Statistical analysis of these curves 
revealed some significant differences between ECF1 and the wild type at two 
time points (5h and 6h). The growth rates of the three strains are very similar; 
the slope of each curve during the logarithmic phase of growth is very similar 
however, 630Δerm may have a shorter lag phase, leading to quicker entry into 
exponential growth, thus the statistical difference in culture optical density at 5h 
and 6h. Other assays rely on growing cultures of each strain to specific growth 
phases however, because they initially require growth to stationary phase 
followed by dilution to a standard culture optical density , any differences in 
growth between the strains used should not affect the results. Because both 
mutated genes are thought to be involved in lipoprotein maturation, it was 
thought that the mutations would have an observable effect on the observed 
size and localisation of certain proteins due to the lack of signal peptide 
cleavage. To investigate this, a combination of protein extractions was 
performed to allow examination of the protein profiles of each strain in various 
cellular locations. This revealed that there were some minor differences 
between the three strains, with one significantly brighter band appearing at 
approximately 24 kDa and a cluster of bands at approximately 15 kDa in a low 
pH glycine extraction of ECF1 which may correspond to bands present in the 
detergent phase of a TX-114 extraction of both 630Δerm and ECF2 but not 
ECF1, suggesting a different profile of lipoproteins associated with the cell wall. 
Neither strain has as different a profile relative to wild type 630 as the 
630ΔermΔlgt strain which previous work has identified as having a substantially 
different protein profile due to a lack of acyl-glyceryl moiety attachment to 
lipoproteins during maturation leading to many lipoproteins being lost to the 
culture media and no-longer being isolated in the lipoprotein-enriching TX-114 
extraction, similar to observations with strains of B. subtilis mutated for lgt (206). 
ECF1 and ECF2 carry mutations in lipoprotein signal peptidase genes which 
would presumably affect sorting and localisation of prolipoproteins  resulting in 
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accumulation of un-directed prolipoproteins as observed in a B. subtilis strain 
mutated for its SPaseII (173), and not directly affect the anchoring of 
lipoproteins to the cell. Additionally, there was no evidence for the loss of 
lipoproteins into the culture filtrate for ECF1 and ECF2 (Figure 4.3.A, Culture 
Filtrate, Lanes 2 and 3) which would indicate a lack of attachment to the cell, 
reflecting the observation in another study (24) where immature lipoproteins of 
S. pneumonia  lacking Lsp were shown to still be attached to the cell surface.  
In previous work, both mutant strains were shown to be more susceptible to the 
toxic effects of malachite green, suggesting a role for correct lipoprotein 
processing in resistance to this stress (34-36). Additional conditions were 
sought that may further demonstrate survival or tolerance differences of these 
strains. Hydrogen peroxide is used extensively in cleaning and disinfection of 
healthcare environments and has shown significant activity against C. difficile 
spores (100, 105, 207)  and there is evidence that Streptococcus pneumoniae 
utilises lipoproteins to protect itself from superoxide and hydrogen peroxide 
through regulation of Mn2+ transport (168), with knockout of the PsaA lipoprotein 
rendering the strain more susceptible to hydrogen peroxide. It is possible that 
disruption of lipoprotein maturation in C. difficile may render the bacterium more 
sensitive to hydrogen peroxide treatment. The ability of ECF1 and ECF2 to 
withstand stress from hydrogen peroxide was examined by incubation with 
varying concentrations of the chemical, revealing an increased ability in both 
strains; at 0.1 mM H2O2 both ECF1 and ECF2 had a significantly higher % 
Survival that the 630 wild type. This was not directly carried through in further 
testing however ECF1 did maintain a significantly higher % Survival at the 
higher concentration of 0.5 mM H2O2. It was also shown that the % Survival of 
all three strains depends on the length of incubation with H2O2; ECF1 and ECF2 
exhibited a significantly increased % Survival at 45 minutes compared to 30 
minutes incubation time with 1 mM H2O2. As these strains are thought to be 
defective in lipoprotein localisation, any similar system to the Mn2+ transport in 
S. pneumoniae which uses the internally localised lipoprotein PsaA could be 
beneficially disrupted in the mutant strains. Further work is required here to 
elucidate how such disruption is beneficial and it is suggested that the reason 
may involve the increased presence of lipoproteins in parts of the cell that are 
particularly affected by the stress, damping the effect.  There may be a greater 
effect from a deficiency in specific lipoproteins such as a PsaA homolog than 
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from disruption of maturation of that lipoprotein or the entire lipoproteome. 
Additionally, further work into the effect of incubation with hydrogen peroxide 
over time may shed more light on the issue. 
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Chapter 5. Expression of C. difficile LspA and LspA2 in E. 
coli 
5.1. Introduction 
It has been shown that the expression of a non-native lipoprotein signal 
peptidase in E. coli induces protection of the bacterium against the antimicrobial 
globomycin (24, 177), the latter having been shown to directly target and inhibit 
the signal peptidase (31). As such, this protection assay provides a method for 
demonstrating the functionality of potential lipoprotein signal peptidases. 
Furthermore, there is potential for this assay to be exploited to utilise analogues 
of globomycin which may have a better activity against lipoprotein signal 
peptidase (32, 93) and there may be potential for modification to utilise the 
antimicrobial myxovirescin which has also been shown to inhibit lipoprotein 
signal peptidases and which has a demonstrable advantage over globomycin 
(33). 
The globomycin protection assay was selected to investigate the functionality of 
the two potential lipoprotein signal peptidases of C. difficile. The first step in this 
process is to generate strains of E. coli able to express either LspA or LspA2 
from C. difficile and as such, the genes encoding each protein were cloned into 
a range of expression vectors. Three vectors were used in this study; two 
proved to be ineffective while the third, pET28a, proved to be successful. Maps 
of the initial expression plasmids and intermediary and final pET28a plasmids 
are shown in Figure 5.1. Only E. coli strains holding pET28a expression 
plasmids produced the anticipated traces on Western blots, thus demonstrating 
the successful generation of strains for use in globomycin protection assays 
with C. difficile lipoprotein signal peptidases.  
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Figure 5.1 Plasmids used for the expression of C. difficile LspA (CD2597) and LspA2 
(CD1903) in E. coli 
A: Expression vectors selected for use in this study. B: pGEM-T Easy TA cloning vector 
holding PCR fragments of CD2597 and CD1903 for insertion into pET28a. C: Maps of 
expression plasmids pEF14 and pEF15; pET28a holding CD2597 and CD1903 respectively, 
cloned downstream of a Lac operator using the Xho1 and Nco1 restriction sites. 
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5.2. Cloning Methodology 
To generate E. coli strains expressing either C. difficile LspA or LspA2, 
expression plasmids were selected to receive PCR products encoding either 
gene. Either the plasmid or the PCR product was required to encode a His-tag 
which would be expressed in combination with the desired C. difficile protein, 
allowing detection of expression via anti-His Western blotting. The generation of 
plasmids and subsequent testing of LspA or LspA2 expression in E. coli are 
described below. 
5.2.1. pQE80: pRL4 and pRL6 
Initially, cloning was planned using pQE80 as the expression plasmid; the 
cloning of both genes was performed in Dr. S. L. Michell’s laboratory at the 
University of Exeter by R. Lawrence (unpublished) and the plasmids donated to 
this study, maps of which are shown in APPENDIX 7. These plasmids, pRL4 
and pRL6 for expression of CD1903 and CD2597 respectively, contain an N-
terminal His-tag co-expressed with the intended protein. The DNA and amino 
acid sequences at the termini of the expressed proteins in both plasmids are 
shown in APPENDIX 6.  
These plasmids were transformed into E. coli C43 (DE3) (BL21), a strain 
commonly used for expression of proteins, and subsequently used in 
expression experiments via isopropyl β-D-1-thiogalactopyranoside (IPTG) 
induction at a concentration of 4 mM IPTG, added once cultures reached an 
optical density of 0.6 at 595 nm. E. coli C43 (DE3) (BL21) holding pNIC-KSA1, 
a plasmid designed for the expression of the CD0873 C. difficile lipoprotein (21) 
with a His-tag was included as a positive control for Western blotting. Proteins 
were extracted from cultures and subjected to SDS-PAGE before use in 
Western blotting; a Western blot of non-inducted and IPTG-induced cultures of 
these strains is shown in Figure 5.2. There is clear expression of CD0873 from 
pNIC-KSA1 in both non-induced and induced cultures (lane 1) indicating some 
leaky expression however expression was much stronger in induced cultures 
indicating that induction was occurring as a response to IPTG treatment. 
Conversely, there is no evidence of expression in lanes 2 and 3, indicating that 
C. difficile LspA and LspA2 are not expressed from pRL4 or pRL6. 
87 
 
Figure 5.2 Anti-His Western blot of protein extractions from non-induced 
and IPTG-induced cultures of E. coli C43 (DE3) (BL21) harbouring 
expression plasmids for C. difficile LspA and LspA2 using pQE80 as a 
backbone 
To demonstrate expression of a protein with a His tag a Western blot was 
performed on protein extractions of IPTG-induced cultures of E. coli C43 (DE3) 
(BL21) holding pRL4 (2), pRL6 (3) or pNIC-KSA1 (1) as a positive control, 
showing a positive result in lane 1 only. Bands were very faint, resulting in high 
exposure of the membrane, causing specking of the background. NI – Non-
Induced, I – Induced. 
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5.2.2. Workflow for subsequent cloning attempts 
As there was no expression observed for E. coli C43 (DE3) (BL21) holding 
either pRL4 or pRL6, indicating a failure to produce CD1903 and CD2597, 
alternative approaches were sought. A cloning workflow was designed for the 
generation of new plasmids for the expression of C. difficile LspA and LspA2 
and is shown in Figure 5.3. This workflow included check steps (red boxes) 
which permitted progress monitoring, allowing detection of errors prior to 
conducting further experimentation.  
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Figure 5.3 Cloning methodology and workflow for the expression of LspA 
and LspA2 from C. difficile in E. coli 
To allow the expression of a C. difficile protein in E. coli, the encoding gene 
must be cloned into an appropriate plasmid that will allow controlled expression. 
Plasmids pBAT4 and pET28a were used for cloning in this study; the C. difficile 
genes lspA (CD2597) and lspA2 (CD1903) were cloned into these plasmids 
using the TA-cloning vector pGEM-T Easy as an intermediary for the PCR 
insert. Various checks were performed during the cloning process (red boxes) 
to allow confirmation of correct cloning and no change in DNA sequence after 
induction of expression. 
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5.2.3. pBAT4: pEF10, pEF11, pEF12 and pEF13 
The second attempt at cloning C. difficile lspA and lspA2 into an expression 
plasmid for expression of LspA and LspA2 in E. coli was performed using the 
vector pBAT4. This vector does not contain a His-tag; therefore it was 
necessary to include a His-tag in the cloning process to be present at the C-
terminus of the proteins. Both lspA and lspA2 possess the uncommon start 
codon TTG (Leucine); it was thought that this may be detrimental to expression 
in E. coli, therefore two sets of plasmids were produced that aimed to eliminate 
this issue, both using the Nco1 restriction site of pBAT4. Firstly pEF10 and 
pEF12 were produced via PCR amplification of lspA and lspA2 respectively 
using primers CD2597_pBAT4_F, CD2597_pBAT4_R, CD1903_pBAT4_F and 
CD1903_pBAT4_R (Table 4) as appropriate. The reverse primers (_R) encoded 
a six moiety His-tag and an Nco1 restriction site at the 3’ end of the products 
and the forward primers (_F) encoded both an Nco1 site and a 10 base 
insertion which changed the start codon of both genes to ATG (Methionine). 
Secondly, pEF11 and pEF13 were produced via the same method utilising the 
reverse primers used for pEF12 and pEF12 with two new forward primers 
CD2597_pBAT4_F2 and CD1903_pBAT4_F2 (Table 4). These forward primers 
again contained an Nco1 site and changed the first two codons of both genes to 
ATG GCT (Methionine, Alanine). These strategies are shown in APPENDIX 6 
and the plasmids produced are shown in APPENDIX 7.  
5.2.3.1. Rare codon usage in pBAT4-derived plasmids 
Due to redundancy in genetic code with more than one codon available for each 
amino acid, species of bacteria can utilize a different codon bias. This is true for 
E. coli and C. difficile and may present a barrier to the expression of C. difficile 
proteins in E. coli, resulting in little or no expression (208). Genes can either be 
codon-optimized for the expression species, altering the gene but not the amino 
acid sequence (140, 209), or the expression strain can be supplemented with 
the tRNAs which complement rare codons. These tRNAs can be encoded on a 
plasmid such as pRARE2; this plasmid is held by the E. coli expression strain 
Rosetta2 (DE3). Both CD2597 and CD1903 have a lot of rare codon usage; 
Rare Codon Caltor (204) analysis of these genes as they appear in pBAT4-
derived plasmids is shown in APPENDIX 9 and demonstrates the level of rare 
codon usage. 
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5.2.3.2. Auto-induction of protein expression from 
pBAT4-derived plasmids 
IPTG is a molecular mimic of a lactose metabolite which activates expression 
from a T7lac promoter in plasmids also containing a lacI gene and a lac 
operator. An in-depth investigation into the mechanisms of this induction has led 
to the development of a system for auto-induction of protein expression in high-
density cultures using a simplified protocol and lactose as the inducing agent 
(205). This system produces much higher yields of protein than IPTG induction, 
producing more easily-detectable protein traces during analysis and was 
therefore selected for use in future expression experiments. 
To investigate expression of C. difficile LspA or LspA2 from pBAT4-derived 
plasmids, E. coli Rosetta2 (DE3) holding these plasmids were grown in 200 ml 
auto-inducing (ZYM-5052) and non-inducing (ZYM-505) media to an optical 
density of approximately 15 at 595 nm. E. coli C43 (DE3) (BL21) holding pNIC-
KSA1 was again included as a positive control. Samples of non-induced and 
auto-induced cultures were subjected to crude protein extraction followed by 
SDS-PAGE and anti-His Western blotting; the Western blot is shown in Figure 
5.4. As before, there is expression of CD0873 (lane C) with no expression of 
His-tagged protein in any other strain (lanes 1 through 5), indicating that there is 
no expression of C. difficile LspA or LspA2 from pEF10, pEF11, pEF12 or 
pEF13. Plasmid DNA was extracted from post-auto-induction cultures and sent 
for sequencing analysis to investigate the possibility that mutations had 
occurred which could prevent protein expression. Only the sample for pEF10 
returned useable results which revealed potential mutations in the regions 
flanking the gene insertion site. This analysis is shown in APPENDIX 8 and the 
potential mutations revealed may explain the lack of expression. 
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Figure 5.4 Anti-His Western blot of protein extractions from non-induced 
and auto-induced cultures of E. coli harbouring expression plasmids for C. 
difficile LspA or LspA2 using pBAT4 as a backbone 
To demonstrate expression of a protein with a His-tag in auto-induced cultures of 
E. coli Rosetta2 (DE3) a Western blot was performed on crude protein 
extractions for 1: pEF10, 2: pEF11, 3: pEF12, 4: pEF13, C: E. coli C43 (DE3) 
(BL21) pNIC-KSA1. A positive result is shown in the control (C) lane only. NI – 
Non-Induced, AI – Auto-induced. 
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5.2.4. pET28a: pEF14 and pEF15 
As no expression was obtained from any of the pBAT4 plasmids, another 
attempt was required. The expression plasmid pET28a was selected for this 
attempt; it has a His-tag downstream of its multiple cloning site, negating the 
need to introduce a tag via PCR. Primers were designed to produce a product 
with an NcoI restriction site at the 5’ end and an XhoI restriction site at the 3’ 
end to allow simpler processing. As discussed in Section 0, the presence of a 
TTG start codon in both genes may be disruptive to expression attempts 
therefore the start codon of each gene was replaced with ATG GGC 
(Methionine, Glycine) using PCR with primers EFTC_pET28a_CD63025970_F 
and EFTC_pET28a_CD63025970_R for lspA to produce pEF14 and 
EFTC_pET28a_CD63019030_F and EFTC_CD63019030_R for lspA2 to 
produce pEF15 (Table 4). 
5.2.4.1. Generation of pEF14 and pEF15 
Following PCR amplification of the genes using the primers named above, 
products were ligated into the TA-cloning vector pGEM-T Easy to produce 
intermediate plasmids (pGEM-T Easy::CD2597pET and pGEM-T 
East::CD1903pET), shown in Figure 5.1.B. The presence of the insert was 
demonstrated by restriction digest, resulting in fragments of expected sizes 
(Figure 5.5). Large volume digests of these plasmids and the vector pET28a 
were conducted, followed by gel electrophoresis and gel extraction of each 
insert and vector; the inserts were then ligated separately to the pET28a vector 
fragment. Ligations and controls were transformed by electroporation into E. coli 
HB101 after unsuccessful attempts to transform into E. coli TOP10 by heat 
shock. Transformants were picked at random for screening by colony PCR; four 
putative pEF14 transformants and three putative pEF15 transformants. Two 
PCR screens utilised either the primers originally used to produce the insert 
fragments or primers for the T7 promoter and T7 terminator (Table 4), sites for 
which are present in pET28a, flanking the multiple cloning site, shown in Figure 
5.5.B and C. All four pEF14 transformants and two pEF15 transformants (lane 7 
and 9) gave a positive result with the insert amplification primers; these six 
transformants were also positive with the T7 primers. The colonies that 
produced the template DNA for the pEF14 transformant in lane 2 and the colony 
that produced the template DNA for the pEF15 transformant in lane 9 were 
taken forward as strains holding pEF14 and pEF15. Rare Codon Caltor analysis 
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of the CD2597 or CD1903-encoding regions of these plasmids is shown in 
APPENDIX 9, revealing the continued presence of high levels of rare codon 
usage. 
5.2.4.2. Cloning error checking by sequencing 
To ensure that no sequence errors were present in the region containing each 
gene in the two plasmids samples were sent for DNA sequencing using the 
primer pair for the T7 promoter and T7 terminator and a primer pair designed to 
bind within each gene allowing sequence reads to cover the entirety of the gene 
sequenced and the neighbouring regions of the plasmid (CD2507_pCheck_L 
and CD2597_pCheck_R for pEF14 and CD1903_pCheck_L and 
CD1903_pCheck_R for pEF15) (Table 4). Figure 5.6 gives a representation of 
the sequencing results showing the alignment of translated results to the in 
silico reference protein amino acid sequence. Sequencing results for both 
genes returned a few ambiguous bases resulting in unknown amino acids which 
are represented by an X in the alignments. Each of these occurrences was due 
to errors in sequencing for one or more reactions however in every case there 
was at least one sequencing reaction that returned the expected base; this can 
be seen in APPENDIX 10, where the sequencing results are shown aligned to 
reference DNA sequences. These results suggest that both CD2597 and 
CD1903 have been successfully cloned into pEF14 and pEF15 respectively and 
that His-tags are present in a correct form. 
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Figure 5.5 Restriction endonuclease digests and colony PCRs to 
demonstrate cloning of CD2597 and CD1903 into pGEM-T Easy (A) and 
pET28a (B & C) 
A: Restriction endonuclease digests of plasmid minipreps of E. coli TOP10 
transformation clones holding pGEM-T Easy with either CD2597 or CD1903 
PCR fragments for cloning into pET28a. Lanes 1 through 4: CD2597 fragment 
undigested minipreps. Lanes 5 through 8: CD1903 fragment undigested 
minipreps. Lanes 9 through 12: CD2597 fragment Nco1/Xho1 digests. Lanes 
12 through 16: CD1903 fragment Nco1/Xho1 digests. B and C: Gels of E. coli 
HB101 colony PCR from pET28a ligation transformations with fragment 
amplification primers (B) and T7 forward and reverse primers (C). Lanes 1 
through 6: CD2597 fragment. Lanes 7 through 11: CD1903 fragment. Whole 
pET28a controls in lanes 5 and 10. PCR Negative controls in lanes 6 and 11.  
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Figure 5.6 Alignment of the DNA sequences of pEF14 and pEF15 to in 
silico references to check for sequence errors 
After initial PCR confirmation, plasmid minipreps samples from E. coli HB101 
holding pEF14 or pEF15 were sequenced to allow identification of sequence 
errors and screening for SNPs or other mutations.  A: Pictorial representation of 
DNA sequencing read alignments to in silico pEF14 reference sequence. B: 
Alignment of the translation of the sequencing reads contig to the in silico 
reference amino acid sequence of CD2597 with 3’ His tag in pEF14 showing 
one potentially variant amino acid. C: Pictorial representation of DNA 
sequencing read alignments to in silico pEF15 reference sequence; poor 
sequence traces were returned for reactions with 2597_pCheckL/R primers and 
did not align. D: Alignment of the translation of the sequencing reads contig to 
the in silico reference amino acid sequence of CD1903 with 3’ His tag in pEF15 
showing 8 potentially variant amino acids. 
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5.2.4.3. Transformation of pET28a, pEF14 and pEF15 into 
E. coli Rosetta2 (DE3) 
Plasmids pEF14, pEF15 and pET28a (for use as an expression-negative 
control) were transformed into E. coli Rosetta2 (DE3) by electroporation. 
Putative transformants were selected for on media containing appropriate 
antibiotics and via colony PCR using primers directed against the T7 promoter 
and T7 terminator regions that flank the multiple insertion site within the 
plasmids. The results of this PCR are shown in Figure 5.7 and reveal that four 
from four tested putative pET28a transformants held pET28a; two from four 
tested putative pEF14 transformants help pEF14 and two from four tested 
putative pEF15 transformants held pEF15. As a result, the colonies which 
produced the brightest PCR products were selected to be carried forward into 
expression experiments: pET28a colony 2, pEF14 colony 1 and pEF15 colony 
2.  
5.2.4.4. Auto-induction of protein expression from pEF14 
and pEF15 and subsequent sequencing analysis 
E. coli Rosetta2 (DE3) strains holding peF14, pEF15 and pET28a were 
subjected to auto-induction as described for strains holding pBAT4-derived 
plasmids (Section 5.2.3.2) with E. coli C43 (DE3) (BL21) pNIC-KSA1 again 
included as a positive control for anti-His Western blotting. To check that no 
mutations had occurred within either pEF14 or pEF15 during auto-induction 
DNA was extracted from post-auto-induction cultures and sent for sequencing 
analysis. The results of this analysis are shown in Figure 5.8; no ambiguous 
amino acids are present in alignments of either set of sequencing results to their 
corresponding references, suggesting that no mutations had occurred. As such, 
LspA and LspA2 produced under auto-inducing conditions by these strains 
would be as identical to the form found in C. difficile as possible, with the 
addition of a His-tag. Alignments of sequencing results contigs to reference 
sequences showing no sequencing differences are shown in APPENDIX 11. 
Because the sequences of pEF14 and pEF15 are correct, proteins expressed 
under auto-inducing conditions which have a His-tag will be correct versions of 
C. difficile LspA and LspA2; Western blotting is required to confirm such 
expression. 
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Figure 5.7 Colony PCR to demonstrate transformation of pET28a, pEF14 
and pEF15 into E. coli Rosetta2 (DE3) 
Gel electrophoresis of colony PCR using T7 forward and reverse primers of E. 
coli Rosetta2 (DE3) transformants with pEF28a, pEF14 or pEF15 was 
performed to confirm successful transformation. A: Lanes 1 through 4: pET29a 
putative transformants. Lanes 5 through 6: pEF14 putative transformants. B: 
Lanes 1 through 4: pEF15 putative transformants. Lane 5: pET28a control. 
Lane 6: pEF14 control. Lane 7: pEF15 control. Lane 8: negative control.  
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Figure 5.8 Analysis of the DNA sequences of pEF14 and pEF15 to in silico 
references to check for sequence errors post auto-induction 
Due to the potential for mutations in expression plasmid sequence during 
induction of expression where the expressed protein may have toxic effects on 
the host cell, post-auto-induction cultures were subjected to plasmid minipreps 
and samples sent for DNA sequencing to allow checking for mutations. A: 
Pictorial representation of DNA sequencing read alignments to in silico pEF14 
reference sequence. B: Alignment of the translation of the sequence contig to 
the translation of the in silico pEF14 reference showing no amino acid 
differences. C: Pictorial representation of DNA sequencing read alignments to 
in silico pEF15 reference sequence. D: Alignment of the translation of the 
sequence contig to the translation of the in silico pEF15 reference showing no 
amino acid differences. 
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5.2.4.1. Anti-His Western blotting 
To demonstrate that C. difficile LspA and LspA2 are expressed under auto-
inducing conditions in E. coli strains holding pEF14 and pEF15 respectively, 
Western blotting was performed on crude protein extractions of non-induced 
and auto-induced cultures. Figure 5.9 shows a safe-stain-treated SDS-PAGE 
gel of these crude protein extractions (A) and the anti-His Western blot (B). 
There were no changes in protein expression profiles between E. coli Rosetta2 
(DE3) strains holding pET28a, pEF14 or pEF15 under either non-inducing or 
auto-inducing conditions. There is, however, a band which changes intensity 
between the non-induced and auto-induced samples of E. coli C43 (DE3) 
(BL21) pNIC-KSA1 at approximately 40 kDa (A Lane 4), indicating expression 
of CD0873 under auto-inducing conditions. Western blotting reveals bands at 
approximately 18 kDa in Lane 2, 21 kDa in Lane 3 and 40 kDa in Lane 4. These 
correspond to the expected protein sizes for LspA, LspA2 and CD0873 
respectively, indicating successful expression of these C. difficile proteins in E. 
coli. Bands are present in both non-induced and auto-induced samples in Lane 
2 and Lane 4, suggesting leaky expression in these strains.  
It is most desirable for C. difficile LspA and LspA2 to be expressed and located 
in the surface layers of the E. coli strain. To test this, samples of auto-induced 
cultures were subjected to low pH glycine protein extractions to enrich for 
surface layer proteins (202) before SDS-PAGE analysis and anti-His Western 
blotting. The Ponceau-S-stained nitrocellulose membrane used in blotting (A) 
and the Western blot (B) are shown in Figure 5.10. The stained membrane may 
show some bands at increased intensities in Lanes 2, 3 and 4, compared to the 
negative pET28a control in Lane 1, that are close to the expected molecular 
weights. The Western blot reveals very clear bands in Lanes 2, 3 and 4 that are 
at the expected sizes for C. difficile LspA, LspA2 and CD0873 respectively. This 
indicates that these proteins are all localised to the surface layer of E. coli when 
expressed under auto-inducing conditions. 
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Figure 5.9 Safe-stain-treated SDS-PAGE and anti-His western blot of crude 
protein extractions of E. coli Rosetta2 (DE3) harbouring pET28a, pEF14 or 
pEF15 and E. coli C43 (DE3) (BL21) harbouring pNIC-KSA1 pre- and post-
auto-induction 
To demonstrate the expression of C. difficile CD2597 and CD1903 in E. coli, 
cultures were subjected to auto-induction and protein extracts examined for the 
presence of the expected proteins. A: SDS-PAGE of crude protein extracts of 
non-induced and auto-induced E. coli Rosetta2 (DE3) or C43 (DE3) (BL21) 
cultures to look for changes in band brightness or novel bands after auto-
induction. B: Anti-His western blot of the SDS-PAGE gel in A to confirm the 
presence of proteins containing a His tag. Both images, 1: pET28a, 2: pEF14, 
3: pEF15, 4: pNIC-KSA1. NI – Non-induced, AI – Auto-induced. 
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Figure 5.10  Ponceau-S-stained nitrocellulose membrane and anti-His 
western blot of low pH glycine protein extractions of E. coli Rosetta2 
(DE3) harbouring pET28a, pEF14 or pEF15 and E. coli C43 (DE3) (BL21) 
harbouring pNIC-KSA1 post-auto-induction 
To demonstrate the localisation of C. difficile CD2597 and CD1903 to the 
surface layers of E. coli when expressed via auto-induction of E. col Rosetta2 
(DE3) holding pEF14 or pEF15, low pH glycine extractions were performed on 
auto-induced cultures and examined for the presence of His-tagged proteins by 
western blotting. A: Ponceau-S-stained nitrocellulose membrane after blotting 
of protein extraction SDS-PAGE. B: Anti-His western of the membrane in A. 
showing very clear expression of His-tagged proteins in all but lane 1. Both 
images, 1: pET28a, 2: pEF14, 3: pEF15, 4: pNIC-KSA1. 
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5.3. Discussion 
Plasmids for the expression of C. difficile LspA and LspA2 in E. coli have been 
generated after two unsuccessful attempts. The first two attempts which used 
either pQE80 or pBAT4 as the expression plasmid did not produce the desired 
end result of clear traces on Western blots probed for His-tagged proteins. The 
first attempt (pQE80) utilised an N-terminal His-tag and the native TTG start 
codon for both proteins. It was thought that these issues may have contributed 
to the lack of expression therefore both were changed for the second attempt 
using pBAT4. In this case, the start codon was changed in two separate cases 
by both an insertion and a forced mutation to ATG. It was also thought that the 
induction of expression was not strong enough therefore auto-induction was 
introduced aiming to produce more E. coli cells each producing a higher yield. 
Again, there was no evidence of expression of either LspA or LspA2 and it was 
found that there may have been mutations within the lacI region of one of the 
final plasmids, suggesting that expression was being prevented by a non-
functional system.  
The third and successful attempt utilised pET28a as the expression plasmid; it 
contains a His-tag downstream of the multiple cloning site, negating the need to 
include one during cloning. Each stage of cloning was rigorously tested to 
ensure that no errors in plasmid sequence were present, maximising the 
probability of success; no errors were found and the plasmids pEF14 (for LspA) 
and pEF15 (for LspA2) were successfully generated. A final barrier to 
expression may have been the frequent usage of rare codons within both lspA 
and lspA2, therefore pEF14 and pEF15 were transformed into E. coli Rosetta2 
(DE3) which holds the pRARE2 plasmid, encoding tRNAs for rare codons. 
Either the use of this strain or the use of pET28a lead to successful expression 
of C. difficile LspA and LspA2. Initial analysis of non-induced and auto-induced 
samples using SDS-PAGE did not reveal evidence of expression with no high 
brightness bands visible in auto-induced samples that were not present in non-
induced samples. After Western blotting, protein bands were only visible at 
expected sizes, indicating that the level of expression may not be as high as 
aimed for. Indeed, the pNIC-KSA1-containing positive control strain exhibited 
far greater expression of CD0873 which was visible via SDS-PAGE. It may be 
necessary to investigate improving the level of expression before pEF14 and 
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pEF15 are used in globomycin protection assays because a low quantity of 
expressed protein can only lead to a low level of protection which may not lead 
to significantly greater strain survival than the E. coli native protein.  
Of interest, it was shown by Western blot of low pH glycine protein extractions 
of auto-induced cultures that LspA, LspA2 and CD0873 were being localised to 
the surface layer of E. coli. This suggests that they will be well located for 
functionality in E. coli, enabling globomycin protection assays to be performed.  
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Chapter 6. Discussion 
Clostridium difficile presents a significant problem to healthcare in many 
countries. At present it primarily affects patients within the healthcare setting; 
however the nature of the disease may be shifting to an increased effect upon 
otherwise healthy individuals in the community. While there has been a 
decrease in cases since the introduction of more rigorous infection control 
measures and improved treatment strategies, the shifting nature of the disease 
and current lack of a truly effective treatment demand that attention is not 
diverted. Various routes for novel treatment of C. difficile infection and disease 
exist, including targeting the two primary toxins, TcdA and TcdB, and preventing 
sporulation or germination, thus removing the transmissible agent of the 
disease. It is also thought that another key area of infection, adhesion, can be 
targeted to combat C. difficile. Lipoproteins have been shown to play many 
roles in bacteria (22), including key roles in virulence (18, 19, 24), and are 
involved in bacterial adhesion (20, 21). As a result, lipoproteins of C. difficile 
and their biosynthesis present a novel area for research to identify new 
methods for treatment. 
The role of lipoprotein signal peptidases in C. difficile has been investigated 
using strains ECF1 and ECF2 which are defective in the genes CD2597 (lspA) 
and CD1903 (lspA2) respectively (34-36). These two genes encode proteins 
LspA and LspA2 which are functional lipoprotein signal peptidases. It has been 
shown here that both proteins possess properties which identify them as 
lipoprotein signal peptidases including the presence of four trans-membrane 
helices in their tertiary structure and the localisation of five amino acid domains 
which are conserved across similar proteins in many bacteria (29, 30, 177). 
LspA is similar to functional homologs in other Clostridia, however LspA2 does 
not display similarity to any of the proteins analysed in this study, indicating that 
it may have been acquired from a different origin during the evolution of C. 
difficile and raising the possibility that it acts upon a subset of lipoproteins. 
Strains ECF1 and ECF2 were subjected to phenotypic analysis which revealed 
a number of differences from and similarities to the 630Δerm wild type strain. 
The growth of all three strains is predominantly the same however there is an 
apparent difference in exponential growth whereby the wild type was observed 
to enter this phase slightly earlier, resulting in greater observable growth in the 
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middle of the phase. Examination of the protein profiles of these strains 
revealed that there was little effect on protein localisation by inactivation of LspA 
and LspA2. This suggests that a lack of signal peptide cleavage does not alter 
the localisation of lipoproteins on a cellular fraction level. Conversely, it has 
previously been shown that inactivation of Lgt causes loss of lipoproteins into 
the culture filtrate due to the lack of anchoring by acyl-glyceryl moieties. 
Previous work demonstrated that ECF1 and ECF2 were more susceptible to the 
antimicrobial effects of malachite green when compared to the wild type (34-
36). In this study, the effect of hydrogen peroxide on these strains was 
investigated. It was shown that both ECF1 and ECF2 were significantly less 
susceptible to this compound than the wild type, with ECF1 the least 
susceptible of the three. This effect may be due to modulation of lipoprotein 
functionality by the lack of signal peptide cleavage. Johnston et al (168) 
demonstrated that knocking out the PsaA lipoprotein of S. pneumoniae caused 
a large reduction in percent survival; complete loss of lipoproteins may have a 
greater effect than disrupted biosynthesis. Lipoproteins and lipoprotein 
biosynthesis may play different roles in the response of C. difficile to these two 
different stresses, thus the difference in the effects of mutation.  For example, 
malachite green is known to have similar effects to the novel antimicrobial 
globomycin which directly targets lipoprotein signal peptidase (31), thus one 
response is directly related to biosynthesis while the other may be related to 
lipoprotein functionality. 
Due to the demonstrated effects of globomycin upon lipoprotein signal 
peptidases and the use of globomycin protection assays in demonstrating the 
role of these proteins in bacteria (24, 177); and the potential for use of 
globomycin or homologs as a treatment, attempts were made to express C. 
difficile LspA and LspA2 in E. coli. To that end, various expression plasmids for 
each protein were generated using three different backbones; pQE80, pBAT4 
and pET28a. The first two attempts were not successful and this is thought to 
be due to a combination of factors including the addition of a His-tag to the 
proteins, methods for modification of the unusual TTG start codon of both genes 
and a lack of accounting for rare codon usage in both genes. The final, and 
successful, attempt using pET28a aimed to overcome these difficulties using an 
altered cloning methodology and the E. coli Rosetta2 (DE3) expression strain 
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which holds pRARE2, a plasmid encoding tRNAs for rare codons. Expression of 
both proteins was induced by auto-induction and demonstrated by anti-His 
Western blotting; no expression was observable by SDS-PAGE alone and the 
level of expression is not as high as expected. The presence of isolated bands 
at the expected molecular weights on the Western blot indicates that the 
proteins were expressed correctly and demonstrate that no other effect was 
being observed. It was also demonstrated that both LspA and LspA2 were 
being localised to the surface layer of E. coli using a low pH glycine protein 
extraction, suggesting that the proteins are located suitably for functionality. 
Strains holding ECF1 and ECF2 are suitable for use in globomycin protection 
assays where expression of the proteins is driven by auto-induction; however 
the system may need optimization to ensure a detectable level of protection is 
achieved. 
Some of the areas covered in this study may benefit from further work. 
Foremost is the use of globomycin protection assays for investigating the role of 
LspA and LspA2 in C. difficile; the tools have been generated but the assay 
needs conducting. There are further phenotypic assays that would also shed 
more light on the role of these two proteins. Expansion of the investigation into 
the effects of hydrogen peroxide upon C. difficile strains would be of benefit and 
should involve a more detailed assessment of the effect of hydrogen peroxide 
concentration over time. In addition to expansion on the assays performed here, 
implementation of adhesion assays using tissue culture cells would allow 
examination of the role of lipoprotein signal peptide cleavage in adhesion of C. 
difficile to host cells. A more detailed study of protein localisation within ECF1 
and ECF2 in comparison to 630Δerm using mass spectrometry may increase 
clarity on the effect of mutation in lspA or lspA2. Not only could any changes in 
lipoprotein localisation be observed but the action of LspA or LspA2 on a given 
lipoprotein could also be examined, perhaps shedding light upon the differing 
roles of these two proteins in C. difficile.  
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Concluding Comments 
Lipoproteins are thought to play a key role in the virulence and pathogenesis of 
C. difficile. Study of their function and of the effects of disrupting lipoprotein 
biosynthesis may shed light on this role and demonstrate potential for treatment 
opportunities. C. difficile encodes two functional lipoprotein signal peptidases: 
LspA and LspA2 which both possess the general properties of proteins of this 
type. Strains with mutations in lspA (ECF1) and lspA2 (ECF2) have been used 
to demonstrate that lipoprotein biosynthesis has an important role in the 
response of C. difficile to malachite green and hydrogen peroxide, providing 
validation of the idea that this process is important in virulence and 
pathogenicity. Further, both LspA and LspA2 have been successfully expressed 
in E. coli using plasmids pEF14 and pEF15, paving the way for further 
investigation into the role of both proteins in C. difficile by globomycin protection 
assays. 
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Appendices 
 
APPENDIX 1 Multiple alignment of lipoprotein signal peptidase proteins from various bacterial species indicating conserved 
regions. Accession numbers are in the left-most column. 
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APPENDIX 2 Protein accession numbers for bacterial lipoprotein signal peptidases used 
in multiple alignments for the generation of Figure 3.1 WebLogo of aligned lipoprotein 
signal peptidase from various bacteria, highlighting the conserved functional amino 
acids and Figure 3.2 Phylogenetic tree of lipoprotein signal peptidase genes from 
various bacteria. A number of proteins have been removed from online databases or 
combined with similar entries thus these proteins are listed here with identical accession 
numbers. 
Protein 
Accession 
Number 
Protein 
Accession 
Number 
    
Clostridium difficile 
LspA2 
Q187L2 
Myxococcus xanthus 
LspA2 
Q1D5G3 
Borrelia burgdorferi 
B31 LspA 
O51425 
Myxococcus xanthus 
LspA1 
Q1D5E9 
Buchnera aphidicola 
str. APS LspA 
P57248 
Myxococcus xanthus 
LspA3 
Q1DFD1 
Rickettsia bellii LspA Q1RI47 
Myxococcus xanthus 
LspA4 
Q1DFD0 
Rickettsia prowazekii 
LspA 
Q9ZDC4 
Brucella melitensis bv. 
1 str. 16M LspA 
Q8YES8 
Rickettsia prowazekii 
str. Madrid E LspA 
Q9ZDC4 
Mesorhizobium loti 
MAFF303099 LspA 
Q98GR1 
Rickettsia typhi LspA Q68WX1 
Sinorhizobium meliloti 
1021 LspA 
Q92SJ3 
Rickettsia Canadensis 
LspA 
A8EZ20 
Mycobacterium 
tuberculosis LspA 
A5WMM6 
Rickettsia felis LspA Q4ULU0 
Mycobacterium leprae 
TN LspA 
Q9X7E7 
Rickettsia akari LspA A8GNC3 
Streptomyces 
coelicolor A3(2) LspA 
Q952X7 
Rickettsia rickettsia 
LspA 
H6Q3C1 
Cupriavidus 
metallidurans CH34 
LspA 
Q1LJB7 
Rickettsia conorii LspA Q92I62 
Ralstonia 
solanacearum 
GMI1000 LspA 
Q8XWL5 
Rickettsia conorii str. 
Malish 7 LspA 
Q92I62 
Neisseria meningitidis 
MC58 LspA 
P65265 
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Caulobacter 
crescentus CB15 LspA 
Q9AAA6 
Neisseria meningitidis 
Z2491 LspA 
P65264 
Chlamydia muridarum 
Nigg LspA 
Q9PJY8 Yersinia pestis LspA Q8ZIL9 
Chlamydia trachomatis 
LspA 
O84413 
Enterobacter 
aerogenes KCTC 2190 
LspA 
P13514 
Chlamydia pneumonia 
LspA 
Q9Z817 
Klemsiella pneumonia 
LspA 
Q9RF47 
Campylobacter jejuni 
LspA 
Q9PIE1 
Escherichia coli K-12 
LspA 
P00804 
Helicobacter pylori 
26695 LspA 
P25178 
Salmonella enterica 
subsp. enterica serovar 
Typhi LspA 
Q8Z9N1 
Helicobacter pylori J99 
LspA 
Q9ZM23 
Salmonella enterica 
subsp. enterica serovar 
Typhimurium str. LT2 
LspA 
Q8ZRY9 
Mycoplasma 
genitalium G37 LspA 
Q49401 
Vibrio cholerae O1 
biovar El Tor str. 
N16961 LspA 
Q9KU46 
Mycoplasma 
pneumonia M129 LspA 
P75484 
Haemophilus 
influenzae Rd KW20 
LspA 
P44975 
Clostridium difficile 
LspA 
Q182T8 
Pasturella multocida 
subsp. multocida str. 
Pm70 LspA 
P57959 
Clostridium 
acetobutylicum ATCC 
824 LspA 
Q97H98 
Pseudomonas 
aeruginosa PAO1 LspA 
Q9HVM5 
Clostridium botulinum 
Ba4 str 657 LspA 
C3KVB1 
Pseudomonas 
fluorescens LspA 
P17942 
Clostridium 
sporogenes ATCC 
15579 LspA 
J7T0X8 
Xyella fastidiosa 9a5c 
LspA 
Q9PAS8 
Clostridium tetani E88 
LspA 
Q894D4 
Serratia marescens 
LspA 
O52213 
Lactococcus lactis 
subsp. Cremoris 
MG1363 LspA 
Q48729 
Nostoc sp. PCC7120 
(Anabaena sp. PCC 
7120) LspA 
Q8YNI8 
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Lactococcus lactis 
subsp. Lactis II1403 
LspA 
Q9CGU5 
Synechocystis sp. PCC 
6803 substr. Kazusa 
LspA 
P73540 
Streptococcus 
pyrogenes serotype 
M1 LspA 
Q9A0D2 
Deinococcus 
rediodurans R1 LspA 
Q9RRU7 
Bacillus halodurans C-
125 LspA 
Q9K9V2 Aquifex aeolicus LspA O67692 
Bacillus subtilis LspA Q45479 
Treponema pallidum 
subsp. pallidum str. 
Nichols LspA 
O83943 
Staphylococcus aureus 
subsp. aureus N315 
LspA 
P65267 
Thermotoga maritime 
LspA 
Q9WYT4 
Staphylococcus 
carnosus subsp. 
carnosus TM300 LspA 
Q59835   
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APPENDIX 3 ClosTron plasmids used to generate C. difficile lspA and lspA2 mutants 
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APPENDIX 4 Statistical analysis of the C. difficile growth curves in Figure 4.2 
Growth curves of wild type and lspA mutant strains of C. difficile, using 
GraphPad Prism 6 
Comparison of curve fitting models, selecting the Sigmoidal dose-response 
(variable slope) as the preferred model with no evidence of inadequate model.  
 
630 erm  lspA  lspA2
Comparison of Fits 
   
Simpler model 
Exponenti al growth 
equation 
Exponenti al growth 
equation 
Exponenti al growth 
equation 
Probability it is correct <0.01% <0.01% <0.01% 
Alternative model 
Sigmoidal dose-response 
(variable slope) 
Sigmoidal dose-response 
(variable slope) 
Sigmoidal dose-response 
(variable slope) 
Probability it is correct >99.99% >99.99% >99.99% 
Ratio of probabilities 
   
Preferred model 
Sigmoidal dose-response 
(variable slope) 
Sigmoidal dose-response 
(variable slope) 
Sigmoidal dose-response 
(variable slope) 
Difference in AICc 66.43 93.7 66.53 
    
Exponential growth equation 
   
Best-fit values 
   
Y0 0.2241 0.1778 0.1868 
k 0.152 0.1731 0.1686 
Tau 6.577 5.777 5.931 
Doubling Time 4.559 4.004 4.111 
Std. Error 
   
Y0 0.04651 0.03904 0.04123 
k 0.02327 0.02396 0.02423 
95% Confidence Intervals 
   
Y0 0.1295 to 0.3187 0.09838 to 0.2572 0.1029 to 0.2706 
k 0.1047 to 0.1994 0.1244 to 0.2218 0.1193 to 0.2179 
Tau 5.016 to 9.552 4.508 to 8.042 4.590 to 8.382 
Doubling Time 3.477 to 6.621 3.125 to 5.574 3.181 to 5.810 
Goodness of Fit 
   
Degrees of Freedom 33 33 33 
R square 0.672 0.7225 0.7054 
Absolute Sum of Squares 2.028 1.744 1.862 
Sy.x 0.2479 0.2299 0.2375 
Replicates test for lack of fit 
   
SD replicates 0.1047 0.05657 0.1007 
SD lack of fit 0.403 0.39 0.386 
Discrepancy (F) 14.82 47.54 14.69 
P value < 0.0001 < 0.0001 < 0.0001 
Evidence of inadequate model? Yes Yes Yes 
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Sigmoidal dose-response 
(variable slope)    
Best-fit values 
   
Bottom 0.04743 0.04385 0.03507 
Top 0.9886 1.007 0.9947 
LogEC50 4.869 5.557 5.309 
HillSlope 0.6482 0.6259 0.6066 
EC50 73993 360709 203788 
Std. Error 
   
Bottom 0.03129 0.01791 0.02865 
Top 0.02725 0.01912 0.02844 
LogEC50 0.1398 0.08802 0.1378 
HillSlope 0.1196 0.06971 0.1031 
95% Confidence Intervals 
   
Bottom -0.01639 to 0.1113 0.007329 to 0.08036 -0.02337 to 0.09350 
Top 0.9330 to 1.044 0.9684 to 1.046 0.9367 to 1.053 
LogEC50 4.584 to 5.154 5.378 to 5.737 5.028 to 5.590 
HillSlope 0.4043 to 0.8922 0.4837 to 0.7680 0.3962 to 0.8169 
EC50 38379 to 142656 238582 to 545351 106695 to 389239 
Goodness of Fit 
   
Degrees of Freedom 31 31 31 
R square 0.9578 0.9836 0.9621 
Absolute Sum of Squares 0.2612 0.1031 0.2392 
Sy.x 0.09179 0.05766 0.08784 
Replicates test for lack of fit 
   
SD replicates 0.1047 0.05657 0.1007 
SD lack of fit 0.04724 0.06024 0.04235 
Discrepancy (F) 0.2036 1.134 0.1769 
P value 0.991 0.3813 0.9946 
Evidence of inadequate model? No No No 
    
Number of points 
   
Analyzed 35 35 35 
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Applying the Sigmoidal dose-response (variable slope) curve fitting model to the 
data sets for all three strains, analysis was conducted to test the suitability of 
one curve for all data sets, revealing that there is enough difference between 
the data sets to require a different curve for each. 
 
630 erm  lspA  lspA2 Global (shared) 
Comparison of Fits 
    
Null hypothesis 
   
One curve for all 
data sets 
Alternative hypothesis 
   
Different curve for 
each data set 
P value 
   
0.0063 
Conclusion (alpha = 0.05) 
   
Reject null 
hypothesis 
Preferred model 
   
Different curve for 
each data set 
F (DFn, DFd) 
   
2.894 (8,93) 
     
Different curve for each 
data set     
Best-fit values 
    
Bottom 0.04743 0.04385 0.03507 
 
Top 0.9886 1.007 0.9947 
 
LogEC50 4.869 5.557 5.309 
 
HillSlope 0.6482 0.6259 0.6066 
 
EC50 73993 360709 203788 
 
Std. Error 
    
Bottom 0.03129 0.01791 0.02865 
 
Top 0.02725 0.01912 0.02844 
 
LogEC50 0.1398 0.08802 0.1378 
 
HillSlope 0.1196 0.06971 0.1031 
 
95% Confidence Intervals 
    
Bottom -0.01639 to 0.1113 
0.007329 to 
0.08036 
-0.02337 to 0.09350 
 
Top 0.9330 to 1.044 0.9684 to 1.046 0.9367 to 1.053 
 
LogEC50 4.584 to 5.154 5.378 to 5.737 5.028 to 5.590 
 
HillSlope 0.4043 to 0.8922 0.4837 to 0.7680 0.3962 to 0.8169 
 
EC50 38379 to 142656 238582 to 545351 106695 to 389239 
 
Goodness of Fit 
    
Degrees of Freedom 31 31 31 
 
R square 0.9578 0.9836 0.9621 
 
Absolute Sum of Squares 0.2612 0.1031 0.2392 
 
Sy.x 0.09179 0.05766 0.08784 
 
     
One curve for all data 
sets     
Best-fit values 
    
Bottom 0.0411 0.0411 0.0411 0.0411 
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Top 0.9962 0.9962 0.9962 0.9962 
LogEC50 5.238 5.238 5.238 5.238 
HillSlope 0.608 0.608 0.608 0.608 
EC50 172825 172825 172825 172825 
Std. Error 
    
Bottom 0.01643 0.01643 0.01643 0.01643 
Top 0.01596 0.01596 0.01596 0.01596 
LogEC50 0.07845 0.07845 0.07845 0.07845 
HillSlope 0.05907 0.05907 0.05907 0.05907 
95% Confidence Intervals 
    
Bottom 
0.008495 to 
0.07370 
0.008495 to 
0.07370 
0.008495 to 
0.07370 
0.008495 to 
0.07370 
Top 0.9645 to 1.028 0.9645 to 1.028 0.9645 to 1.028 0.9645 to 1.028 
LogEC50 5.082 to 5.393 5.082 to 5.393 5.082 to 5.393 5.082 to 5.393 
HillSlope 0.4908 to 0.7251 0.4908 to 0.7251 0.4908 to 0.7251 0.4908 to 0.7251 
EC50 120775 to 247306 120775 to 247306 120775 to 247306 120775 to 247306 
Goodness of Fit 
    
Degrees of Freedom 
   
101 
R square 0.9432 0.9748 0.9613 0.96 
Absolute Sum of Squares 0.351 0.1581 0.2446 0.7537 
Sy.x 
   
0.08639 
Constraints 
    
Bottom Bottom is shared Bottom is shared Bottom is shared 
 
Top Top is shared Top is shared Top is shared 
 
LogEC50 LogEC50 is shared LogEC50 is shared LogEC50 is shared 
 
HillSlope HillSlope is shared HillSlope is shared HillSlope is shared 
 
     
Number of points 
    
Analyzed 35 35 35 
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To identify which data points are different enough from the others for the 
particular time point to cause a different curve to be required for each data set, 
a two-way ANOVA with Tukey’s multiple comparisons test was performed,  
comparing the mean of values for each strain at a given time point with the 
means of the other strains. This test indicates that at 5h and 6h (Rows 6 and 7), 
630Δerm is significantly different to ECF1 (ΔlspA) but not ECF2 (ΔlspA2). 
Within each row, 
compare columns 
(simple effects 
within rows) 
        
         
Number of families 11 
       
Number of 
comparisons per 
family 
3 
       
Alpha 0.05 
       
         
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant? Summary 
Adjusted 
P Value 
Adjusted 
P Value 
  
     
  
  
Row 1 
    
  
  
630 erm vs. 
lspA 
0 
-0.1762 to 
0.1762 
No ns 
> 0.9999 > 0.9999 
  
630 erm vs. 
lspA2 
0.003333 
-0.1729 to 
0.1795 
No ns 
0.9989 0.9989 
  
lspA vs. lspA2 0.003333 
-0.1729 to 
0.1795 
No ns 
0.9989 0.9989 
  
     
  
  
Row 2 
    
  
  
630 erm vs. 
lspA 
0.006667 
-0.1695 to 
0.1829 
No ns 
0.9955 0.9955 
  
630 erm vs. 
lspA2 
0.01 
-0.1662 to 
0.1862 
No ns 
0.9898 0.9898 
  
lspA vs. lspA2 0.003333 
-0.1729 to 
0.1795 
No ns 
0.9989 0.9989 
  
     
  
  
Row 3 
    
  
  
630 erm vs. 
lspA 
0.02 
-0.1562 to 
0.1962 
No ns 
0.9600 0.9600 
  
630 erm vs. 
lspA2 
0.01667 
-0.1595 to 
0.1929 
No ns 
0.9721 0.9721 
  
lspA vs. lspA2
-
0.003333 
-0.1795 to 
0.1729 
No ns 
0.9989 0.9989 
  
     
  
  
Row 4 
    
  
  
630 erm vs. 
lspA 
0.04 
-0.1362 to 
0.2162 
No ns 
0.8497 0.8497 
  
630 erm vs. 
lspA2 
0.04 
-0.1362 to 
0.2162 
No ns 
0.8497 0.8497 
  
lspA vs. lspA2 2.48E-09 
-0.1762 to 
0.1762 
No ns 
> 0.9999 > 0.9999 
  
     
  
  
Row 5 
    
  
  
630 erm vs. 
lspA 
0.1067 
-0.06953 to 
0.2829 
No ns 
0.3208 0.3208 
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630 erm vs. 
lspA2 
0.09667 
-0.07953 to 
0.2729 
No ns 
0.3917 0.3917 
  
lspA vs. lspA2 -0.01 
-0.1862 to 
0.1662 
No ns 
0.9898 0.9898 
  
     
  
  
Row 6 
    
  
  
630 erm vs. 
 lspA 
0.1967 
0.02047 to 
0.3729 
Yes * 
0.0251 0.0251 
  
630 erm vs. 
 lspA2 
0.1167 
-0.05953 to 
0.2929 
No ns 
0.2581 0.2581 
  
 lspA vs.  lspA2 -0.08 
-0.2562 to 
0.09619 
No ns 
0.5244 0.5244 
  
     
  
  
Row 7 
    
  
  
630 erm vs. 
 lspA 
0.2 
0.02381 to 
0.3762 
Yes * 
0.0223 0.0223 
  
630 erm vs. 
 lspA2 
0.1467 
-0.02953 to 
0.3229 
No ns 
0.1212 0.1212 
  
 lspA vs.  lspA2 -0.05333 
-0.2295 to 
0.1229 
No ns 
0.7491 0.7491 
  
     
  
  
Row 8 
    
  
  
630 erm vs. 
lspA 
0.06667 
-0.1095 to 
0.2429 
No ns 
0.6377 0.6377 
  
630 erm vs. 
lspA2 
0.04667 
-0.1295 to 
0.2229 
No ns 
0.8014 0.8014 
  
lspA vs. lspA2 -0.02 
-0.1962 to 
0.1562 
No ns 
0.9600 0.9600 
  
     
  
  
Row 9 
    
  
  
630 erm vs. 
lspA 
-0.04 
-0.2162 to 
0.1362 
No ns 
0.8497 0.8497 
  
630 erm vs. 
lspA2 
-
0.006667 
-0.1829 to 
0.1695 
No ns 
0.9955 0.9955 
  
lspA vs. lspA2 0.03333 
-0.1429 to 
0.2095 
No ns 
0.8930 0.8930 
  
     
  
  
Row 10 
    
  
  
630 erm vs. 
lspA 
-0.02333 
-0.1995 to 
0.1529 
No ns 
0.9460 0.9460 
  
630 erm vs. 
lspA2 
-
0.003333 
-0.1795 to 
0.1729 
No ns 
0.9989 0.9989 
  
lspA vs. lspA2 0.02 
-0.1562 to 
0.1962 
No ns 
0.9600 0.9600 
  
     
  
  
Row 11 
    
  
  
630 erm vs. 
lspA 
0 
-0.1762 to 
0.1762 
No ns 
> 0.9999 > 0.9999 
  
630 erm vs. 
lspA2 
0 
-0.1762 to 
0.1762 
No ns 
> 0.9999 > 0.9999 
  
lspA vs. lspA2 0 
-0.1762 to 
0.1762 
No ns 
> 0.9999 > 0.9999 
  
         
         
Test details Mean 1 Mean 2 Mean Diff. 
SE of 
diff. 
N1 N2 q DF 
         
Row 1 
        
630 erm vs. 
lspA 
0.03667 0.03667 0 0.07348 3 3 0 66 
630 erm vs. 
lspA2 
0.03667 0.03333 0.003333 0.07348 3 3 0.06415 66 
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lspA vs. lspA2 0.03667 0.03333 0.003333 0.07348 3 3 0.06415 66 
         
Row 2 
        
630 erm vs. 
lspA 
0.04 0.03333 0.006667 0.07348 3 3 0.1283 66 
630 erm vs. 
lspA2 
0.04 0.03 0.01 0.07348 3 3 0.1925 66 
lspA vs. lspA2 0.03333 0.03 0.003333 0.07348 3 3 0.06415 66 
         
Row 3 
        
630 erm vs. 
lspA 
0.06333 0.04333 0.02 0.07348 3 3 0.3849 66 
630 erm vs. 
lspA2 
0.06333 0.04667 0.01667 0.07348 3 3 0.3208 66 
lspA vs. lspA2 0.04333 0.04667 -0.003333 0.07348 3 3 0.06415 66 
         
Row 4 
        
630 erm vs. 
lspA 
0.12 0.08 0.04 0.07348 3 3 0.7698 66 
630 erm vs. 
lspA2 
0.12 0.08 0.04 0.07348 3 3 0.7698 66 
lspA vs. lspA2 0.08 0.08 2.484E-09 0.07348 3 3 4.78E-08 66 
         
Row 5 
        
630 erm vs. 
lspA 
0.26 0.1533 0.1067 0.07348 3 3 2.053 66 
630 erm vs. 
lspA2 
0.26 0.1633 0.09667 0.07348 3 3 1.86 66 
lspA vs. lspA2 0.1533 0.1633 -0.01 0.07348 3 3 0.1925 66 
         
Row 6 
        
630 erm vs. 
lspA 
0.5433 0.3467 0.1967 0.07348 3 3 3.785 66 
630 erm vs. 
lspA2 
0.5433 0.4267 0.1167 0.07348 3 3 2.245 66 
lspA vs. lspA2 0.3467 0.4267 -0.08 0.07348 3 3 1.54 66 
         
Row 7 
        
630 erm vs. 
lspA 
0.85 0.65 0.2 0.07348 3 3 3.849 66 
630 erm vs. 
lspA2 
0.85 0.7033 0.1467 0.07348 3 3 2.823 66 
lspA vs. lspA2 0.65 0.7033 -0.05333 0.07348 3 3 1.026 66 
         
Row 8 
        
630 erm vs. 
lspA 
0.9767 0.91 0.06667 0.07348 3 3 1.283 66 
630 erm vs. 
lspA2 
0.9767 0.93 0.04667 0.07348 3 3 0.8981 66 
lspA vs. lspA2 0.91 0.93 -0.02 0.07348 3 3 0.3849 66 
         
Row 9 
        
630 erm vs. 
lspA 
1 1.04 -0.04 0.07348 3 3 0.7698 66 
630 erm vs. 
lspA2 
1 1.007 -0.006667 0.07348 3 3 0.1283 66 
lspA vs. lspA2 1.04 1.007 0.03333 0.07348 3 3 0.6415 66 
         
Row 10 
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630 erm vs. 
lspA 
1.003 1.027 -0.02333 0.07348 3 3 0.4491 66 
630 erm vs. 
lspA2 
1.003 1.007 -0.003333 0.07348 3 3 0.06415 66 
lspA vs. lspA2 1.027 1.007 0.02 0.07348 3 3 0.3849 66 
         
Row 11 
        
630 erm vs. 
lspA 
0.98 0.98 0 0.07348 3 3 0 66 
630 erm vs. 
lspA2 
0.98 0.98 0 0.07348 3 3 0 66 
lspA vs. lspA2 0.98 0.98 0 0.07348 3 3 0 66 
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APPENDIX 5 Statistical analysis of C. difficile survival under hydrogen peroxide 
stress using GraphPad Prism 6 
Statistical analysis for Figure 4.4 Effect of hydrogen peroxide concentration 
on survival of C. difficile strains, using GraphPad Prism 6 two-way ANOVA 
followed by Tukey’s multiple comparisons test to compare the differences 
between the survival of each strain at each concentration. 
Source of Variation 
% of total 
variation 
P value 
P value 
summary 
Significant? 
    
Interaction 4.365 < 0.0001 **** Yes 
    
Time 81.34 < 0.0001 **** Yes 
    
Column Factor 0.3871 0.1692 ns No 
    
Subjects (matching) 2.426 0.6721 ns No 
    
         
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P value 
   
Interaction 11329 8 1416 
F (8, 96) = 
4.561 
P < 
0.0001    
Time 211078 4 52770 
F (4, 96) = 
170.0 
P < 
0.0001    
Column Factor 1005 2 502.3 
F (2, 24) = 
1.915 
P = 
0.1692    
Subjects (matching) 6296 24 262.3 
F (24, 96) 
= 0.8450 
P = 
0.6721    
Residual 29804 96 310.5 
     
         
Number of missing 
values 
0 
       
         
         
Within each row, compare columns (simple effects within rows) 
         
Number of families 5 
       
Number of 
comparisons per family 
3 
       
Alpha 0.05 
       
         
Tukey's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary 
Adjusted 
P Value    
         
0 
        
    630 Derm vs. DlspA 12.72 
-6.688 to 
32.12 
No ns 0.2692 
   
    630 Derm vs. DlspA2 10.56 
-8.841 to 
29.97 
No ns 0.4026 
   
    DlspA vs. DlspA2 -2.153 
-21.56 to 
17.25 
No ns 0.9625 
   
         
0.01 
        
    630 Derm vs. DlspA 5.289 
-14.11 to 
24.69 
No ns 0.7945 
   
    630 Derm vs. DlspA2 -18.31 
-37.72 to 
1.090 
No ns 0.0687 
   
    DlspA vs. DlspA2 -23.6 
-43.01 to -
4.199 
Yes * 0.0127 
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0.05 
        
    630 Derm vs. DlspA 22.63 3.228 to 42.03 Yes * 0.0178 
   
    630 Derm vs. DlspA2 19.29 
-0.1147 to 
38.69 
No ns 0.0517 
   
    DlspA vs. DlspA2 -3.342 
-22.75 to 
16.06 
No ns 0.9121 
   
         
0.1 
        
    630 Derm vs. DlspA -29.76 
-49.16 to -
10.35 
Yes ** 0.0012 
   
    630 Derm vs. DlspA2 -33.44 
-52.85 to -
14.04 
Yes *** 0.0002 
   
    DlspA vs. DlspA2 -3.684 
-23.09 to 
15.72 
No ns 0.8942 
   
         
1 
        
    630 Derm vs. DlspA 0.006667 
-19.40 to 
19.41 
No ns > 0.9999 
   
    630 Derm vs. DlspA2 -0.01 
-19.41 to 
19.39 
No ns > 0.9999 
   
    DlspA vs. DlspA2 -0.01667 
-19.42 to 
19.39 
No ns > 0.9999 
   
         
         
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF 
         
0 
        
    630 Derm vs. DlspA 104.2 91.45 12.72 8.176 9 9 2.199 120 
    630 Derm vs. DlspA2 104.2 93.61 10.56 8.176 9 9 1.827 120 
    DlspA vs. DlspA2 91.45 93.61 -2.153 8.176 9 9 0.3725 120 
         
0.01 
        
    630 Derm vs. DlspA 93.06 87.77 5.289 8.176 9 9 0.9148 120 
    630 Derm vs. DlspA2 93.06 111.4 -18.31 8.176 9 9 3.168 120 
    DlspA vs. DlspA2 87.77 111.4 -23.6 8.176 9 9 4.082 120 
         
0.05 
        
    630 Derm vs. DlspA 105.1 82.44 22.63 8.176 9 9 3.914 120 
    630 Derm vs. DlspA2 105.1 85.78 19.29 8.176 9 9 3.336 120 
    DlspA vs. DlspA2 82.44 85.78 -3.342 8.176 9 9 0.5781 120 
         
0.1 
        
    630 Derm vs. DlspA 14.25 44.01 -29.76 8.176 9 9 5.147 120 
    630 Derm vs. DlspA2 14.25 47.7 -33.44 8.176 9 9 5.784 120 
    DlspA vs. DlspA2 44.01 47.7 -3.684 8.176 9 9 0.6373 120 
         
1 
        
    630 Derm vs. DlspA 0.006667 0 0.006667 8.176 9 9 0.00115 120 
    630 Derm vs. DlspA2 0.006667 0.01667 -0.01 8.176 9 9 0.00173 120 
    DlspA vs. DlspA2 0 0.01667 -0.01667 8.176 9 9 0.00288 120 
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Statistical analysis for Figure 4.5 Further investigation of the effect of 
hydrogen peroxide concentration on survival of C. difficile strains, using 
GraphPad Prism 6 two-way ANOVA followed by Tukey’s multiple comparisons 
test to compare the differences between the survival of each strain at each 
concentration. 
Source of Variation 
% of 
total 
variation 
P value 
P value 
summary 
Significant? 
    
Interaction 8.204 < 0.0001 **** Yes 
    
Time 26.34 < 0.0001 **** Yes 
    
Column Factor 0.575 0.4684 ns No 
    
Subjects (matching) 29.28 0.0045 ** Yes 
    
         
ANOVA table SS DF MS F (DFn, DFd) P value 
   
Interaction 117770 4 29443 
F (4, 156) = 
8.987 
P < 
0.0001    
Time 378133 2 189067 
F (2, 156) = 
57.71 
P < 
0.0001    
Column Factor 8254 2 4127 
F (2, 78) = 
0.7658 
P = 
0.4684    
Subjects (matching) 420362 78 5389 
F (78, 156) = 
1.645 
P = 
0.0045    
Residual 511062 156 3276 
     
         
W ithin each row, compare columns (simple effects within rows)  
         
Number of families 3 
       
Number of 
comparisons per 
family 
3 
       
Alpha 0.05 
       
         
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significant? Summary 
Adjusted 
P Value    
         
  0.1 
        
630 erm vs. lspA 60.57 
20.06 to 
101.1 
Yes ** 0.0015 
   
630 erm vs. lspA2 34.65 
-5.848 to 
75.16 
No ns 0.1101 
   
lspA vs. lspA2 -25.91 
-66.41 to 
14.59 
No ns 0.2885 
   
         
  0.5 
        
630 erm vs. lspA -65.06 
-105.6 to -
24.56 
Yes *** 0.0006 
   
630 erm vs. lspA2 -0.02185 
-40.52 to 
40.48 
No ns > 0.9999 
   
lspA vs. lspA2 65.04 
24.53 to 
105.5 
Yes *** 0.0006 
   
         
  1 
        
630 erm vs. lspA 0.01889 
-40.48 to 
40.52 
No ns > 0.9999 
   
630 erm vs. lspA2 0.01852 
-40.48 to 
40.52 
No ns > 0.9999 
   
lspA vs. lspA2 -0.00037 
-40.50 to 
40.50 
No ns > 0.9999 
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Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF 
         
  0.1 
        
630 erm vs. lspA 124.1 63.57 60.57 17.17 27 27 4.988 234 
630 erm vs. lspA2 124.1 89.48 34.65 17.17 27 27 2.854 234 
lspA vs. lspA2 63.57 89.48 -25.91 17.17 27 27 2.134 234 
         
  0.5 
        
630 erm vs. lspA 0.002222 65.06 -65.06 17.17 27 27 5.358 234 
630 erm vs. lspA2 0.002222 0.02407 -0.02185 17.17 27 27 0.0018 234 
lspA vs. lspA2 65.06 0.02407 65.04 17.17 27 27 5.356 234 
         
  1 
        
630 erm vs. lspA 0.01889 0 0.01889 17.17 27 27 0.001556 234 
630 erm vs. lspA2 0.01889 0.0003704 0.01852 17.17 27 27 0.001525 234 
lspA vs. lspA2 0 0.0003704 -0.0003704 17.17 27 27 3.05E-05 234 
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Statistical analysis for Figure 4.6 Effect of incubation time with hydrogen 
peroxide on survival of C. difficile strains, using GraphPad Prism 6 two-way 
ANOVA followed by Sidak’s multiple comparisons test to compare the 
difference in survival of each strain after the two time periods. 
Source of 
Variation 
% of total 
variation 
P value 
P value 
summary 
Significant? 
    
Interaction 2.764 0.3811 ns No 
    
Time 28.44 0.0001 *** Yes 
    
Column Factor 2.764 0.3811 ns No 
    
Subjects 
(matching) 
33.02 0.5 ns No 
    
         
ANOVA table SS DF MS F (DFn, DFd) P value 
   
Interaction 0.000004466 2 0.000002233 
F (2, 24) = 
1.005 
P = 0.3811 
   
Time 0.00004594 1 0.00004594 
F (1, 24) = 
20.67 
P = 0.0001 
   
Column Factor 0.000004466 2 0.000002233 
F (2, 24) = 
1.005 
P = 0.3811 
   
Subjects 
(matching) 
0.00005335 24 0.000002223 
F (24, 24) = 
1.000 
P = 0.5000 
   
Residual 0.00005335 24 0.000002223 
     
         
Number of 
missing values 
0 
       
         
Compare each cell mean with the other cell mean in that column. 
  
         
Number of 
families 
1 
       
Number of 
comparisons per 
family 
3 
       
Alpha 0.05 
       
         
Sidak's multiple 
comparisons test 
Mean Diff. 
95% CI of 
diff. 
Significant? Summary 
Adjusted 
P Value    
         
30 - 45 
        
630 erm -0.001057 
-0.002860 
to 
0.0007466 
No ns 0.3764 
   
lspA -0.002414 
-0.004217 
to -
0.0006103 
Yes ** 0.0065 
   
lspA2 -0.002063 
-0.003867 
to -
0.0002600 
Yes * 0.0215 
   
         
         
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF 
         
30 - 45 
        
630 erm 0 0.001057 -0.001057 0.0007028 9 9 1.504 24 
lspA 0 0.002414 -0.002414 0.0007028 9 9 3.434 24 
lspA2 0 0.002063 -0.002063 0.0007028 9 9 2.936 24 
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APPENDIX 6 Cloning strategy for expression of C. difficile LspA and LspA2 in E. coli using vectors pQE80 and pBAT4 
To allow for detection of expressed protein the addition of a His tag was required (5’ end for pQE80 and 3’ end for pBAT4), and 
amplification primers were designed to have this effect. Due to the uncommon TTG start codon for both lspA and lspA2, the cloning 
strategy for pBAT4 was to introduce an ATG start codon via forced cloning with the amplification primers plus an Nco1 restriction site 
(C^CATGG). Two methods were used: the deletion of two bases to generate a different first pair (pEF11 and pEF13) or the insertion of 
10 bases to extend the start of the gene (pEF10 and pEF12).  
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APPENDIX 7 Plasmids generated for expression of C. difficile LspA and LspA2 
in E. coli that did not result in detectable expression 
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pEF10             1  taatacgactcactatagggaattgtgagcggataacaattcctctagaaataattttgtttaactttaagaaggagatatatcc ATGgc 
Consensus       428  .......................................................................................... 
 
pEF10            91  tatgctatatatattaataataattctactcataggtttagaccaactgtctaaaatatgggtattgaataatttggtggatgtatcaac 
Consensus       518  .......................................................................................... 
 
pEF10           181  aataccaataataaataatgtatttcatttaacttatgtcgaaaatagaggtgcagcatttggattattacaaaataatcaatggatatt 
Consensus       608  .......................................................................................... 
 
pEF10           271  tataattgttgcattacttgcaacagtatttggactatactatcttaatacaaggaaagtacatatatttggaaggttgggaattatatt 
Consensus       698  .......................................................................................... 
 
pEF10           361  aattatatctggtgcattgggaaatctaattgatagagtacgattaggttttgtagtagattacttcgactttagaattatatgggaata 
Consensus       788  .......................................................................................... 
 
pEF10           451  tgtattcaatatagctgatgtatttgtagttgtaggaactgtgtttttatgtatatatgttttattttttgaaagtaaaagtaggcacca 
Consensus       878  .......................................................................................... 
 
pEF10           541  ccaccaccaccacTAAccatggatatcgaattcgtcgacctcgagggatccgggccctctagatgcggccgcatgcataagcttgagtat 
Consensus       968  .......................................................................................... 
 
pEF10           631  tctatagtgtcacctaaatcccagcttgatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataa 
Consensus       1058 .......................................................................................... 
 
pEF10           721  ctagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccggataacctggcgtaatagcg 
Consensus       1148 .......................................................................................... 
 
pEF10           811  aagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggaaattgtaaacgttaatattttgttaaaattcgc 
Consensus       1238 .................................................................r........................ 
 
pEF10           901  gttaaatatttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagatagg 
Consensus       1328 .......w.................................................................................. 
 
pEF10           991  gttgagtgttgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatcagggcga 
Consensus       1418 .......................................................................................... 
 
pEF10           1081 tggcccactacagcttgcatgcctgcaggtcggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgc 
Consensus       1508 ........nnn...................................................................y........... 
 
pEF10           1171 gttgcgcTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTG-CATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGC 
Consensus       1598 .................................................n........................................ 
 
pEF10           1260 GTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGC 
Consensus       1688 ................................................................................r......... 
 
pEF10           1350 AAGCGGTCCACGCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTGACGGCGGGATATAACATGAGCTGTCTTCGGTATCG 
Consensus       1778 ..............................s.......................r.........n......................... 
 
APPENDIX 8 DNA sequencing data analysis for pEF10 
DNA samples of pBAT4-derieved expression plasmids were sent for DNA sequencing to ascertain the cause of a lack of protein 
expression. Only the sample for pEF10 returned useable sequence results which were combined into the data labelled Sample below. 
While the CD2597 sequence was correct (bold face with start and stop codons in capitals), there were many potential mutations in both 
the region after CD2597 and in lacI (all capitals), possibly explaining the lack of expression. 
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APPENDIX 9 Rare Codon Caltor analysis of CD2597 and CD1903 genes as found in plasmids peF10, pEF11, pEF12, pEF13, pEF14 
and pEF15, showing considerable rare codon usage in all cases. 
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APPENDIX 10 Alignments of DNA sequencing results for pEF14 and pEF15 to 
in silico references, further to the information in Figure 5.6 Alignment of the 
DNA sequences of pEF14 and pEF15 to in silico references to check for 
sequence errors 
 
Sequence alignment for pEF14. The start and stop codons (ATG and TGA) and 
represented in capitals, with the His tag (6X cac) in bold and larger case. In 
addition, the source of the single potentially variable amino acid seen in the 
protein alignment is indicated in capitals at pEF14 reference base 5272. The 
variant amino acid is a result of two sequencing traces (2597_pCheckL and 
T7R) returning an ambiguous base with the other two traces returning the 
expected base; it was thus assumed that the base was correct in the plasmid. 
 
pEF14 Reference  5041 tttgtttaactttaagaaggagatataccATGggcctatatatattaataataattctac 
2597_pCheckL          tttgtttnnctttaagaaggagatntnccATGggcctatatatattantaataattctgc 
T7R                   tttatttaactttaagaaggaaatataccATGggcctatatatattaataataattctac 
T7F                       tttaactttaanaaggagatataccATGggcctatatatattaataataattctac 
 
pEF14 Reference  5101 tcataggtttagaccaactgtctaaaatatgggtattgaataatttggtggatgtatcaa 
2597_pCheckL          tcataggtttagaccaactgtctagaataggggtattgaataatttggtggacgtatcaa 
T7R         tcataggtttagaccaactgtctaaaatatgggtattgaataatttggtggatgtatcaa 
T7F          tcataggtttagaccaactgtctaaaatatgggtattgaataatttggtggatgtatcaa 
 
pEF14 Reference  5161 caataccaataataaataatgtatttcatttaacttatgtcgaaaatagaggtgcagcat 
2597_pCheckL          ccataccantaatnaataatgtatttcatttaacttaggtcgaacatagaggtgcagcat 
T7R       caataccaataataaataatgtatttcatttaacatatgtcgaaaatagaggtgcagcat 
T7F         caataccaataataaataatgtatttcatttaacttatgtcgaaaatagaggtgcagcat 
 
pEF14 Reference  5221 ttggattattacaaaataatcaatggatatttataattgttgcattacttgcaAcagtat 
2597_pCheckL          ttggattattacaaaataatcaatggatactgataattgttgcattacttgcaNcagtgt 
T7R      ttggattattacaaaataatcaatggatattaataattgttgcattacttgcaNcagtat 
T7F          ttggattattacaaaataatcaatggatatttataattgttgcattacttgcaAcagtat 
2596_pCheckR            tataattnntgcattacttgcaAcagtat 
 
pEF14 Reference  5281 ttggactatactatcttaatacaaggaaagtacatatatttggaaggttgggaattatat 
2597_pCheckL          ttggactatcctatcttgatacaaggaaagtacatatat 
T7R      ttgggctatactatgaaaatacaaggaaagtacatatatttggaaggttgggaattatat 
T7F          ttggactatactatcttaatacaaggaaagtacatatatttggaaggttgggaattatat 
2596_pCheckR      ttggactatactatcttaatacaaggaaagtacatatatttggaaggttgggaattatat 
 
pEF14 Reference  5341 taattatatctggtgcattgggaaatctaattgatagagtacgattaggttttgtagtag 
T7R       taattatatctggtgcattgggaaatctaattgatagagtacgattaggttttgtagtag 
T7F          taattatatctggtgcattgggaaatctaattgatagagtacgattaggttttgtagtag 
2596_pCheckR      taattatatctggtgcattgggaaatctaattgatagagtacgattaggttttgtagnag 
 
pEF14 Reference  5401 attacttcgactttagaattatatgggaatatgtattcaatatagctgatgtatttgtag 
T7R      attacttcgactttagaattatatgggaatatgtattcaatatagntgatgtatttgtag 
T7F         attacttcgactttagaattatatgggaatatgtattcaatatagctgatgtatttgtag 
2596_pCheckR      attacttcgactttagaattatatgggaatatgtattcaatatagctgatgtatttgnag 
 
pEF14 Reference  5461 ttgtaggaactgtgtttttatgtatatatgttttattttttgaaagtaaaagtaggctcg 
T7R       ttgtaggaactgtgtttttatgtatatatgttttattttttgaaagtaaaagtaggctcg 
T7F          ttgtaggaactgtgtttttatgtatatatgttttattttttgaaagtaaaagtaggctcg 
2596_pCheckR      ttgttggaactgtgtttttacgtatatatgtcacattttgagaaag 
 
pEF14 Reference  5521 agcaccaccaccaccaccacTGAgatccggctgctaacaaagcccgaaaggaagctgagt 
T7R         agcaccaccgccaccaccanT GNgatccggctgctaac 
T7F          agcaccaccaccaccaccacTGAnatccggctgctaacaaagcccgaaaggaagctgagt 
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Sequence alignment for pEF15. The start and stop codons (ATG and TGA) and 
represented in capitals, with the His tag (6X cac) in bold and larger case. While 
DNA sequencing was performed with 4 primers, neither pEF15_pCheckR nor 
pEF15_pCheckL reactions returned sequence traces that could be aligned to 
the in silico reference. The sources of the potentially variant amino acids seen 
in the alignment in Figure 5.6 are where one sequence trace has returned a 
different amino acid to the other (red bases). In all cases, one sequence trace 
returned the expected base, thus it is not expected that there are any sequence 
differences in the plasmid. 
 
pEF15 Reference  5039 attttgtttaactttaagaaggagatataccATGggccaaggaggtgttaatatcaggca 
T7R       attttgtttaactttaagaaggagatataccATGggccaaggaggtgttaatatcaggca 
T7F                  actttaagaaggagatataccATGggccaaggaggtgttaatatcnggca 
 
pEF15 Reference  5099 agtaaagtcttttgtttttccagttatatccttaatattcttagaccaaattagcaaagt 
T7R      agtaaagtcttttgtttttccagttatatccttaatattcttagaccaaattagcaaagt 
T7F      agtaaagtcttttgtttttccngttatatccttaatattcttagaccaaattagcaaagt 
 
pEF15 Reference  5159 tcttataggattattcttaatggactttgaaattgatataattgggaaatttttaagatt 
T7R      tcttataggattattcttaatggactttgaaattgatataattgggaaatttttaagatt 
T7F      tcttataggattattcttaatggactttgaaattgatataattgggaaatttttaagatt 
 
pEF15 Reference  5219 caatcctgttcaaaatacaaatctatcttatgggggaaactttattggtattctatctaa 
T7R      caatcctgttcaaaatacaaatctatcttatgggggaaactttattggtattctatctaa 
T7F      caatcctgttcaaaatacaaatctatcttatgggggaaactttattggtattctatctaa 
 
pEF15 Reference  5279 tttatgggtattggtattgtttaacattttagttatattagttattatatctggatatgc 
T7R      tttatgggtattggtattgtttaacattttagttatattagttattatatctggatatgc 
T7F      tttatgggtattggtattgtttaacattttacttatattagttattatatcnggatatgc 
 
pEF15 Reference  5339 tttttataaatcaaaaaatgaacaaacaagctattcagtaaaagtaattatgtcttgtgg 
T7R      tttttataaatcaaaaaatgaacaaacaagctattcagtaaaagtaattatgtcttgtgg 
T7F      tttttataaatcaaaaaatgaacaaacaagctattcagtaaaagtaattatgtcttgtgg 
 
pEF15 Reference  5399 acttgctggtacaatatgtagcttgatagataaattattttggggaggaagtttagattt 
T7R      acttgctggtacaatatgtagcttgatagataaattattttggggaggaagtttagattt 
T7F      acttgctggtacaatatgtagcttgatagataaattattttggggaggaagtttagattt 
 
pEF15 Reference  5459 tttgcagataccaagcttttttattttcgacttaaaagactgctaccttactgttgcaga 
T7R      tttgcagataccaagcttttttattttcgacttaaaagactgctaccttactgttgcaga 
T7F      tttgcagataccaagcttttttattttcgacttaaaagactgctaccttactgttgcaga 
 
pEF15 Reference  5519 aataatatttgttgtcataggaattttgcataatagagaaatatcaatgaaagaatacat 
T7R      aataatatttgttgtcataggaattttgcataatagagaaatatcaatgaaagaatacat 
T7F      aataatatttgttgtcannngaattttgcataatanagaaatatcaatgaaagaatacat 
 
pEF15 Reference  5579 atatttttgctatcgtcagtttaaaagactcgagcaccaccaccaccaccacTGAgatcc 
T7R      atatttttgctatcgtcagtttaaaagactcgagcaccaccaccaccaccacTGAga 
T7F      atatttttgctatcgtcagtttaaaagactccagcaccaccaccaccaccacTGAtatcc 
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APPENDIX 11 Alignments of DNA sequencing results for pEF14 and pEF15 to 
in silico references using DNA extracted from post-auto-induction culture, 
further to the information in Figure 5.8 Analysis of the DNA sequences of 
pEF14 and pEF15 to in silico references to check for sequence errors post 
auto-induction 
 
Sequence alignment for pEF14. The sequence alignment is displayed in 
reverse, thus the start codon is represented by CAT and the stop codon by 
TCA, both in larger font than the rest of the alignment. The His tag is coded for 
by 6 repeated GTG codons. The Insert Sequence is the contig of combined 
DNA sequencing results. There are no DNA sequence differences between the 
insert and the in silico reference, leading to a lack of amino acid sequence 
differences, indicating successful correct cloning. 
 
pEF14 Reference    1 ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAA 
Insert Sequence  691 ............................................................ 
 
pEF14 Reference   61 GGGGTTATGCTAGTTATTGCTCAGCGGTGGCAGCAGCCAACTCAGCTTCCTTTCGGGCTT 
Insert Sequence  751 ............................................................ 
 
pEF14 Reference  121 TGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGCCTACTTTTACTTTCAA 
Insert Sequence  811 ............................................................ 
 
pEF14 Reference  181 AAAATAAAACATATATACATAAAAACACAGTTCCTACAACTACAAATACATCAGCTATAT 
Insert Sequence  871 ............................................................ 
 
pEF14 Reference  241 TGAATACATATTCCCATATAATTCTAAAGTCGAAGTAATCTACTACAAAACCTAATCGTA 
Insert Sequence  931 ............................................................ 
 
pEF14 Reference  301 CTCTATCAATTAGATTTCCCAATGCACCAGATATAATTAATATAATTCCCAACCTTCCAA 
Insert Sequence  991 ............................................................ 
 
pEF14 Reference  361 ATATATGTACTTTCCTTGTATTAAGATAGTATAGTCCAAATACTGTTGCAAGTAATGCAA 
Insert Sequence 1051 ............................................................ 
 
pEF14 Reference  421 CAATTATAAATATCCATTGATTATTTTGTAATAATCCAAATGCTGCACCTCTATTTTCGA 
Insert Sequence 1111 ............................................................ 
 
pEF14 Reference  481 CATAAGTTAAATGAAATACATTATTTATTATTGGTATTGTTGATACATCCACCAAATTAT 
Insert Sequence 1171 ............................................................ 
 
pEF14 Reference  541 TCAATACCCATATTTTAGACAGTTGGTCTAAACCTATGAGTAGAATTATTATTAATATAT 
Insert Sequence 1231 ............................................................ 
 
pEF14 Reference  601 ATAGGCCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAATTG 
Insert Sequence 1291 ............................................................ 
 
pEF14 Reference  661 TTATCCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTCGA 
Insert Sequence 1351 ............................................................ 
 
pEF14 Reference  721 TCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCG 
Insert Sequence 1411 ............................................................ 
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Sequence alignment for pEF15. The sequence alignment is displayed in 
reverse, thus the start codon is represented by CAT and the stop codon by 
TCA, both in larger font than the rest of the alignment. The His tag is coded for 
by 6 repeated GTG codons. The Insert Sequence is the contig of combined 
DNA sequencing results. There are no DNA sequence differences between the 
insert and the in silico reference, leading to a lack of amino acid sequence 
differences, indicating successful correct cloning. 
 
pEF15 Reference    1 ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAA 
Insert Sequence 1209 ............................................................ 
 
pEF15 Reference   61 GGGGTTATGCTAGTTATTGCTCAGCGGTGGCAGCAGCCAACTCAGCTTCCTTTCGGGCTT 
Insert Sequence 1149 ............................................................ 
 
pEF15 Reference  121 TGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTCTTTTAAACTGACGAT 
Insert Sequence 1089 ............................................................ 
 
pEF15 Reference  181 AGCAAAAATATATGTATTCTTTCATTGATATTTCTCTATTATGCAAAATTCCTATGACAA 
Insert Sequence 1029 ............................................................ 
 
pEF15 Reference  241 CAAATATTATTTCTGCAACAGTAAGGTAGCAGTCTTTTAAGTCGAAAATAAAAAAGCTTG 
Insert Sequence  969 ............................................................ 
 
pEF15 Reference  301 GTATCTGCAAAAAATCTAAACTTCCTCCCCAAAATAATTTATCTATCAAGCTACATATTG 
Insert Sequence  909 ............................................................ 
 
pEF15 Reference  361 TACCAGCAAGTCCACAAGACATAATTACTTTTACTGAATAGCTTGTTTGTTCATTTTTTG 
Insert Sequence  849 ............................................................ 
 
pEF15 Reference  421 ATTTATAAAAAGCATATCCAGATATAATAACTAATATAACTAAAATGTTAAACAATACCA 
Insert Sequence  789 ............................................................ 
 
pEF15 Reference  481 ATACCCATAAATTAGATAGAATACCAATAAAGTTTCCCCCATAAGATAGATTTGTATTTT 
Insert Sequence  729 ............................................................ 
 
pEF15 Reference  541 GAACAGGATTGAATCTTAAAAATTTCCCAATTATATCAATTTCAAAGTCCATTAAGAATA 
Insert Sequence  669 ............................................................ 
 
pEF15 Reference  601 ATCCTATAAGAACTTTGCTAATTTGGTCTAAGAATATTAAGGATATAACTGGAAAAACAA 
Insert Sequence  609 ............................................................ 
 
pEF15 Reference  661 AAGACTTTACTTGCCTGATATTAACACCTCCTTGGCCCATGGTATATCTCCTTCTTAAAG 
Insert Sequence  549 ............................................................ 
 
pEF15 Reference  721 TTAAACAAAATTATTTCTAGAGGGGAATTGTTATCCGCTCACAATTCCCCTATAGTGAGT 
Insert Sequence  489 ............................................................ 
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APPENDIX 12 Permission to reuse material from Paetzel M, Karla A, Strynadka 
NC, Dalbey RE. Signal peptidases. Chemical reviews. 2002 Dec;102(12):4549-
80 (29), as reprinted forFigure 1.4 Schematic of type II signal peptidase 
structure and proteolytic mechanism 
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